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Abstract

NOVEL ANALOGS OF m-CHLOROPHENYLGUANIDINE AS 5-HT3 RECEPTOR
LIGANDS
By Katie Elizabeth Alix
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Małgorzata Dukat, Associate Professor
Department of Medicinal Chemistry

Serotonin receptors play a variety of functional roles in the body. Some
indications and treatment claims for one of the classes of serotonin receptors, the 5-HT3
receptor family, include: anxiety, depression, chemotherapy- and radiation-induced
emesis, constipation, irritable bowel syndrome, pain, drug addiction, and satiety control.
A 5-HT3 receptor partial agonist, MD-354, served as a lead compound in the
development of new 5-HT3 receptor ligands. Using halogenated analogs the study
investigated their effect on binding to the 5-HT3 receptor. Conformationally-constrained
analogs (quinazolines) were shown to be a novel class of 5-HT3 receptor antagonists. The

xvi
log P values were determined for several analogs, and indicated that these ligands should
be able to penetrate the blood-brain barrier. A homology model of the 5-HT3 receptor
was built and the docking modes were assessed for these two series. Quinazolines were
investigated for antidepressant properties using the mouse tail suspension test, and were
shown to possess antidepressant-like activity.

I. Introduction

Serotonin (5-HT) research in the central nervous system (CNS) has come a long
way since serotonin was first proposed to be a neurotransmitter.1 After the identification
of the first two serotonin receptors in 1957,2 the list has expanded several times to include
seven major families and their subtypes. Most serotonin receptors are G-protein coupledreceptors (GPCRs); however, one family of serotonin receptors consists of ligand-gated
ion-channel (LGIC) receptors—the 5-HT3 receptor family.
Ligand-gated ion-channels are fast acting. Once a ligand activates the receptor, an
agonist, binds to the receptor; the receptor is depolarized and ions quickly travel through
the pore, changing the synaptic polarity. 5-HT3 receptors are generally co-localized on
nerve endings with other neurotransmitter receptors. The change in synaptic polarity from
activation of 5-HT3 receptors can stimulate the release of nearby neurotransmitters (i.e.,
dopamine,

norepinephrine,

glutamate,

acetylcholine,

γ-aminobutyric

acid,

and

serotonin).3,4 Since 5-HT3 receptors can stimulate the release of so many
neurotransmitters it seems to have the potential to be involved in several different
functions.
Most notably, 5-HT3 receptors are known for their antagonists, most of which are
clinically available as anti-emetics. These drugs are effective in the treatment of
chemotherapy- and radiation-induced emesis.5 From the investigations into treating
1

2
emesis, other 5-HT3 receptor antagonists have been identified to be useful in the
treatment of irritable bowel syndrome (IBS).5 The 5-HT3 receptors have also been
implicated in depression, pain modulation, the reward pathway, schizophrenia, and
anxiety.5,6 No known therapeutic function has been identified for 5-HT3 receptor
agonists.
m-Chlorophenylguanidine (mCPG; MD-354) is a partial agonist at the 5-HT3
receptor, it behaves as an agonist in some assays and as antagonist in other assays; but
binds with high affinity to the 5-HT3 receptor (Ki = 35 nM).7,8 Because of the partial
agonist characteristic, it would be valuable to develop novel analogs to explore which
aspects are necessary for binding to the 5-HT3 receptor as well as ways to improve
binding affinity.
The 5-HT3 receptors are located in the CNS as well as in the periphery. In order to
study the effects of the 5-HT3 receptors in the CNS, agents must be able to get into the
brain and cross the blood-brain barrier (BBB). MD-354 has a log P value of -0.64
suggesting it may not be able to easily penetrate the BBB;9 thus, developing analogs that
can cross the BBB would be necessary for studying 5-HT3 receptors in the CNS.
In drug development, molecular modeling has proven to be a powerful tool. Since
the structure of the 5-HT3 receptor has yet to be determined by X-ray crystallography,
homology models of the receptor can be built from other ligand-gated ion-channels of the
Cys-loop family whose structure has been determined to identify possible binding modes
of known agents and aid in the design of new agents.

3
From data compiled since 1960, depression affects up to 38% of cancer
patients.10,11 The idea of being able to treat the emesis from chemotherapy as well as the
depression with one drug is an inviting possibility. Both 5-HT3 receptor antagonists and
agonists have been shown to behave as antidepressants in the forced swim and tail
suspension tests in rodents.12-17 This suggests that a variety of classes of 5-HT3 receptor
agents are capable of having the same interactions with the 5-HT3 receptor, an analysis of
selected agents for antidepressant-like properties may yield a novel class of
antidepressants.

II. Background:
A. History of Serotonin

Evidence for the existence of serotonin (5-hydroxytryptamine; 5-HT; 1) (Figure
1) was detected as early as 1868 as a vasoconstrictor.18 However, its isolation did not
occur for more than another half century. Independently, Erspamer and Vialli19 isolated
enteramine in the late 1930s from enterochromaffin cells in the gut and Rapport et al.20
isolated serotonin as a beef serum vasoconstrictor substance in 1948. In 1949, Rapport
determined the structure of serotonin as 5-hydroxytryptamine.21 But it was not until 1952
that Erspamer and Asero discovered that enteramine and serotonin were one and the
same.22

1
Figure 1. The structure of serotonin (5-HT).

The central nervous system (CNS) story of serotonin began in 1953 when Twarog
and Page discovered serotonin in dog, rat, and rabbit brains;23 later, in 1954, Twarog

4

5
proposed serotonin to be a neurotransmitter.1 Independently Woolley and Shaw,24 and
Gaddum and Hameed25 proposed that the action of 5-HT in the brain and in the gut could
be antagonized by the hallucinogen LSD ((+)-lysergic acid diethylamide).
Serotonin has been implicated in a number of different processes in both the
periphery and central nervous systems and has been shown to play a role in alcoholism
and drug abuse, cognitive disorders, depression, anxiety, schizophrenia, chemotherapyand radiation-induced emesis, constipation, irritable bowel syndrome, migraines,
fibromyalgia, pain, obesity, appetite disorders, and autism.6
B. Classification of 5-HT Receptors

The first definitive receptors for 5-HT were identified by Gaddum and Picarelli in
1957.2 These receptors were originally called D- and M-receptors because they were
antagonized by dibenzyline and morphine, respectively. In 1979 Peroutka and Snyder
used

14

C and 3H techniques to determine 5-HT receptor subtypes in vitro.26 A receptor

classification scheme was proposed by the Nomenclature Committee of the International
Union of Pharmacology (IUPHAR) in 1992.27 Table 1 provides the general criteria for
receptor classification as provided by IUPHAR.28 Receptors are classified by operational
(drug-binding), structural (sequence of the receptor), and transductional (receptor-effector
coupling) characteristics. Upper case lettering is used when the receptor has been
identified in whole cells while lower case lettering is used when identifying recombinant
receptors.

6
To date there are seven major families of serotonin receptors (5-HT1-5-HT7). All,
but the 5-HT3 (5-HT3A-5-HT3E) receptors, belong to the G-protein coupled-receptor
(GPCR) superfamily. The 5-HT3 receptors belong to the Cys-loop ligand-gated ionchannel (LGIC) receptor superfamily. The 5-HT1 (5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e, 5HT1F) receptors inhibit adenylate cyclase (AC); the 5-HT2 (5-HT2A, 5-HT2B, 5-HT2C)
receptors stimulate phospholipase C (PLC) production. The 5-HT4, 5-HT6, 5-HT7 (5HT7A, 5-HT7B, 5-HT7D) receptors stimulate adenylate cyclase while a second messenger
system for activation of the 5-ht5a and 5-ht5b receptors has yet to be defined.6,28-30
Table 1. Criteria for receptor characterization.28

Criteria
Operational
a. Selective agonists
b. Selective antagonists
c. Ligand-binding affinities
Structural
d. Molecular structure

Transductional
e. Intracellular transduction
mechanisms

Definition
Agonists showing high selectivity for a particular
receptor compared to their potencies at other receptors
need to be identified.
Receptor-blocking drugs are needed that can block the
actions of agonists by blocking the receptor.
Dissociation constants for ligands in binding studies
should correlate with data from functional studies.
Amino acid sequence of the receptor protein provides
evidence for receptor identity; relative homologies
can be used for classification and defining families
and subfamilies.
Information that further defines a superfamily and any
information that may be indicative of the nature of the
intracellular protein structure.

1. G-Protein Coupled-Receptors

GPCRs are characterized by seven transmembrane-spanning helicies (TM1-TM7),
three intracellular loops (IL1-IL3), and three extracellular loops (EL1-EL3) (as reviewed

7
by Lagerström and Schiöth).31 The amine terminus is extracellular and the carboxyl
terminus is intracellular. One of the intracellular loops, usually IL2 or IL3, is coupled to a
heterotrimeric G-protein, which upon ligand binding dissociates to a βγ subunit and an α
subunit to activate second messenger systems (e.g., PLC and AC). There are many other
GPCRs including the adrenergic receptors and rhodopsin receptors.
2. Ligand-Gated Ion-Channel Receptors

5-HT3-type receptors are ligand-gated ion-channel receptors and are part of the
Cys-loop superfamily.32 Structurally, these receptors are pentamers with each subunit
(Figure 2) consisting of a very large extracellular domain (ECD) containing the amine
terminus and the ligand-binding domain, four transmembrane-spanning helicies (M1M4), a short intracellular loop connecting M1 to M2, a short extracellular loop
connecting M2 to M3, an intracellular loop between M3 and M4, and an extracellular
carboxyl terminus.33,34 The M2 helix of each subunit makes up the inner lining of the
cationic pore. Upon binding of an agonist, the receptor depolarizes and allows the influx
of cations through the pore. This change in synaptic polarity may stimulate the release of
other nearby neurotransmitters. The long ECD that is associated with the amine terminus
consists of six putative loops (A-F); loops A, B, and C make up the principle side of the
binding interface and loops D, E, and F make up the complementary side of the binding
interface (Figure 3).35 Incidentally, the binding site for agonists and competitive
antagonists lies at the interface of two protomers. On the C loop there are two cysteines
separated by 13 amino acids; they form a disulfide linkage and thus a Cys-loop. Other

8

Figure 2. Schematic representation of a single protomer of a LGIC receptor.

Figure 3. Bottom veiw of the homopentameric h5-HT3A ECD (left). Side view of the
ligand binding domain; loops A, B, and C are on one protomer (“principle subunit”; red)
and loops D, E, and F are on the adjacent protomer (“complementary subunit”; blue)
(right).

9
LGIC receptors include nicotinic acetylcholine (nACh), γ-aminobutyric acid type A
(GABAA), and glycine receptors.5,6 There is a 22-30% sequence homology between the
5-HT3A receptor subunit sequence and the α-subunits of other members of the LGIC
family.36 Ortells and Lunt proposed that 5-HT3 receptors are a possible common ancestor
of all LGIC receptors.37 To date, there are no X-ray crystal structures of 5-HT3 receptors;
however, various acetylcholine binding proteins’ structures have been identified by X-ray
crystallography.38-40 The structure of a nicotinic acetylcholine receptor has been derived
using electron microscopy.41 Also, the α1 subunit ECD of a mouse nACh receptor bound
to α-bungarotoxin has been crystallized and the structure determined.42 Since the 5-HT3
receptor subunits share features with nACh receptors (i.e., protein sequence homology
between 5-HT3A receptor subunit sequences and the α subunit of other LGIC receptors is
22-30%),36 homology models for 5-HT3 receptors can be developed based on the crystal
structures available.38-42 There have been some reports of chimeric receptors between
different members of the LGIC family.35,43
C. 5-HT3 Receptors
1. Classification

5-HT3 receptors were identified as the original M receptor but were later renamed
5-HT3 receptors by Bradley et al.44 The 5-HT3A receptor subtype was initially cloned by
Maricq et al. in 1991 from NCB-20 murine hybridoma cells.45 The first human 5-HT3
receptors were cloned from the hippocampus, amygdala, and colon.46,47 The human
HTR3A gene is located on chromosome 11 and each receptor subunit consists of 478
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amino acids.48 Species orthologs of the 5-HT3A receptor have also been identified in the
rat,47 mouse,44 dog,49 guinea pig,50 and ferret.51 There are a few splice variants of the 5HT3A receptor subunits: 5-HT3AS (i.e., short), h5-HT3AT (i.e., short, truncated) and h5HT3AL (i.e., long).52 The 5-HT3AS receptor subunit is found in mouse, rat, and guinea
pig, and has six fewer amino acids in the loop between M3 and M4.44,47,50 The h5HT3AT receptor subunit, found in humans, only has 238 amino acids and a single
transmembrane helix (M1).52 The h5-HT3AL receptor subunit, found in humans, has an
additional 32 amino acids in the loop between M2 and M3.52 These isoforms do not form
functional homomeric receptors but form functional heteromeric receptors with the native
h5-HT3A receptor subunits.52 Receptors containing h5-HT3AT subunits have decelerated
desensitization and therefore, a larger response to Ca2+ fluxes.52 Those receptors
containing h5-HT3AL subunits accelerate desensitization and have reduced Ca2+ fluxes.52
The 5-HT3B receptor subtype was isolated in 1999 by screening human genomic
sequence data by Davies et al.53 It shares 41% amino acid sequence identity with h5HT3A receptors and is also located on chromosome 11, and each subunit has 441 amino
acids.53,54 Rat and mouse orthologs of the 5-HT3B receptor have also been identified.55
The 5-HT3C, 5-HT3D, 5-HT3E receptor subtypes were cloned by Niesler et al.56 and
Karnovsky et al.57 independently in 2003. The 5-HT3D receptor subtype as predicted by
Niesler et al.56 lacks a signal peptide and most of the amine terminus ECD including the
Cys-loop; not surprisingly, each subunit only has 279 amino acids. The 5-HT3C and 5HT3E receptor subtypes share 36% and 39% amino acid sequence homology with h5HT3A receptors,57 and have 447 and 471 amino acids, respectively. All three of these
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subtypes are located on chromosome 3 and were originally thought to be exclusive to
humans. 5-HT3C and 5-HT3E have since been found in chimp and dog.58
2. Structure and Distribution

Only the 5-HT3A receptor subtype forms homomeric receptors; the remainder of
the subtypes form functional heteromeric receptors with 5-HT3A subunits.53,54,59 The
composition and stoichiometry of native heteromeric 5-HT3 receptors has yet to be
determined.60,61 When h5-HT3A and h5-HT3B receptor subunits were epitope-tagged and
expressed heterologously in tsA-201 cells they formed heteromeric receptors containing
three 5-HT3B and two 5-HT3A receptor subunits with the order of B-B-A-B-A.62 This
stoichiometry was determined by atomic force microscopy. However, the heteromeric 5HT3AB receptors have different biophysical properties than the homomeric 5-HT3A
receptors.53,54 The pharmacological profile of the heteromeric receptors containing 5HT3C, 5HT3D, or 5-HT3E subunits in combination with 5-HT3A subunits is similar to
homomeric 5-HT3A receptors or heteromeric 5-HT3AB receptors59,61 but the biophysical
properties have yet to be determined. HTR3A-C genes are expressed both centrally and in
the periphery, whereas HTR3D and HTR3E genes are only expressed in the
gastrointestinal (GI) tract.61 In addition, 5-HT3C-E receptors appear to be absent in
rodents.61 Within the CNS there are two main regions in which 5-HT3 receptors are
expressed: the dorsal vagal complex and the forebrain.63-65 The dorsal vagal complex
contains the nucleus tractus solitarius (NTS), area postrema, and dorsal motor nucleus of
the vagus nerve. These are important for the vomiting reflex.64 Within the forebrain,
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human 5-HT3 receptor recognition sites have been located in the caudate nucleus,
putamen, hippocampus, and amygdala.66-68 The caudate nucleus and putamen are
involved in learning while the hippocampus and amygdala (part of the limbic system) are
involved in memory processing.60
3. Pharmacology and Biological Functions

Several different in vivo and in vitro assays are employed for the identification of
agonists and antagonists at the 5-HT3 receptors. The von Bezold-Jarisch reflex is one of
the most prominent in vivo assays used.69 Upon administration of an agonist there is a
cardiopulmonary reflex in which bradycardia is the most prominent response (the other
two responses of the reflex are apnea and hypotension). An antagonist would be any
agent that blocks the response of the agonist. Another in vivo assay used is the ferret or
shrew emesis assay.70 Cisplatin is given to the animal to induce vomiting; an antagonist
would block this effect, while an agonist would induce vomiting when administered
alone. After an application of cantharidin to human skin a blister forms. When 5-HT is
applied to the base of the blister it causes pain which can be reversed by 5-HT3 receptor
antagonists.71 In vitro, the most commonly used assay is contraction of guinea pig ileum.2
An agonist produces contraction while an antagonist would block the contraction of the
agonist. Other in vitro assays include the rabbit vagus nerve (5-HT3 receptor agonists
produce an increase in the amplitude of C-fiber action potentials), the isolated rabbit heart
(release of noradrenaline and acetylcholine by 5-HT3 receptor agonists), and the uptake
of [14C]guanidinium in NG108-15 cells (5-HT3 receptor agonists stimulate ion
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accumulation).71 Some agents have been shown to be agonists in one assay while
antagonists in another assay. For example, m-chlorophenylguanidine (mCPG; MD-354;
2; Figure 4) behaves as an agonist in the von Bezold-Jarisch assay7 and emesis assays in

shrews,8 but at higher doses behaves as an antagonist in the cisplatin-induced emesis
assay.8 A novel functional assay was developed based on micromechanical measurement
of membrane receptor binding.72 The deflection of microcantilevers is dependent on
molecular binding and thus radiolabelled ligands are unnecessary.73 These particular
microcantilevers are modified with a membrane preparation containing 5-HT3AS
receptors and bend on the application of the 5-HT3 receptor agonist 5-HT or the 5-HT3
receptor antagonist MDL-72222.72 Agonists and competitive antagonists compete for the
binding on these membrane preparations.

2
Figure 4. The structure of m-chlorophenylguanidine (mCPG; MD-354).

5-HT3 receptors are concentrated in regions of the brain that are involved in the
vomiting reflex, anxiety and depression, pain processing, and the reward system.5,6 The
receptors are predominantly found in presynaptic regions with the exception of the
hippocampus in which they are postsynaptic.5 This localization on nerve endings
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contributes to 5-HT3 receptors modulating the release of neurotransmitters.5 Activation of
5-HT3 receptors modulates the release of various neurotransmitters and neuropeptides
including: dopamine, norepinephrine, glutamate, acetylcholine, GABA, and even
serotonin.3,4 Presynaptic activation provides for the influx of Ca2+, whereas postsynaptic
activation (i.e., in the hippocampus) provides for the influx of K+ and Na+.22
There are six 5-HT3 receptor antagonists (Figure 5) on the global clinical market
and five are effective in the treatment of chemotherapy-induced and radiation-induced
emesis (i.e., ondansetron (3), granisetron (4), tropisetron (5), dolasetron (6), and
palonosetron (7)).5 These agents are ineffective against motion sickness and
apomorphine-induced emesis.6,74 They induce a complete blockade of both central and
peripheral 5-HT3 receptors. The sixth available 5-HT3 receptor antagonist on the market
is alosetron (8) which is used for the treatment of irritable bowel syndrome (IBS).5
Recently, the application for the approval by the FDA of cilansetron was withdrawn, but
it is a 5-HT3 receptor antagonist also used in the treatment of IBS.75
5-HT3 receptors have been implicated in IBS and constipation. In diarrheaprominent IBS, the 5-HT3 receptor antagonist, ondansetron (3), has been shown to
alleviate symptoms but can also cause excessive constipation.76 It is thought that 5-HT3
receptor partial agonists would be able to alleviate the symptoms without causing sideeffects.76 Constipation, which is normally treated by laxatives that cause side-effects, can
also be treated by 5-HT3 receptor agonists.77
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Figure 5. Clinically available 5-HT3 receptor antagonists: ondansetron (3), granisetron
(4), tropisetron (5), dolasetron (6), palonosetron (7), and alosetron (8).
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5-HT3 receptors are located in the dorsal horn as well as in other regions involved
in pain modulation.78 Stimulation of these receptors produces an antinociceptive effect.5
MD-354 (2), a 5-HT3 receptor partial agonist, has been shown to selectively potentiate
the antinociceptive action of clonidine in the mouse tail-flick assay without potentiating
clonidine’s sedative effects.79
In the last decade, 5-HT3 receptors have also been implicated in depression.80
Ondansetron (3), a 5-HT3 receptor antagonist, has been shown to be active as an
antidepressant in both the tail suspension and forced swim tests (for a detailed description
see Section 7) in mice (Swiss 0.01 – 0.1 μg/kg, ip; albino, 0.25 – 2 mg/kg, ip).15,17 In
earlier studies, however, ondansetron (3) (0.01 μg/kg, ip) had been shown to be inactive
in the mouse forced swim test by itself but potentiates the sub-active doses of the
antidepressants fluoxetine (16 mg/kg), citalopram (16 mg/kg), and fluvoxamine (8
mg/kg).16 In another study, the 5-HT3 receptor antagonist bemesetron (9) (Figure 10) has
been shown to be active by itself (3 mg/kg, sc) and at inactive doses (1 mg/kg, sc) in
combination with inactive doses of ketamine (12.5-25 mg/kg, sc) in the mouse tail
suspension test (C57BL/6J/Han).13 The exact involvement of 5-HT3 receptors in
depression has yet to be identified. However, Bhatnager et al.81 demonstrated that there
are differences between wild-type (WT) and 5-HT3 receptor knock-out (KO) male and
female mice in the forced swim and the defensive withdrawal tests (light-dark test). In the
mouse forced swim test, KO females exhibited increased behavioral indices of depression
type behavior in comparison to WT females, thus showing that 5-HT3 receptors do play a
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role in depression. In addition, single nucleotide polymorphisms on the HTR3B gene have
been linked with major depression.82
5-HT3 receptor antagonists may also be effective in influencing the reward system
of drug abuse because of the modulation of dopamine.5 Other possible clinical
implications for 5-HT3 receptor antagonists include cognitive functions, schizophrenia,
satiety, and anxiety.5
4. Agonists

Since serotonin (1; 5-HT3 Ki ≈ 1000 nM) is a tryptamine, the first ligands studied
were other tryptamine analogs. Methylation of the indole nucleus of 5-HT (e.g., 2methyl-5-hydroxytryptamine; 10; Ki ≈ 1300 nM) (Figure 6) was found to result in an
agent that was less potent but more selective than 5-HT as a 5-HT3 receptor agonist.83,84
However, 10 is rapidly metabolized and has difficulty crossing the blood-brain barrier
(BBB).85 Methylation of the terminal amine was also examined.86,87 N-Monomethyl-5HT was shown to be active in the depolarization of superior cervical ganglion cells (it has
an equipotent molar ratio (epmr) of 1.3 relative to 5-HT) while N,N-dimethyl— (11) and
N,N,N-trimethyl—5-HT (5-HTQ; 12) were found to have increased activity (empr of 0.08
and 0.01, respectively).87 Similarly, in binding affinity assays, 11 and 12 were found to
bind with enhanced affinity (Ki ≈ 280 nM and 75 nM, respectively) relative to 5-HT.86 5HTQ (12) has a permanent positive charge that was well tolerated by 5-HT3 receptors (Ki
≈ 75 nM), but 5-HTQ does not readily cross the BBB.86 Longer terminal amine
substituents and locking the terminal amine into a ring abolished affinity.86
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Figure 6. The structure of methylated analogs of 5-HT.

Another of the first agonists investigated were the arylpiperazines (Figure 7).7,88
Quipazine (2-(1-piperazinyl)quinoline; 13; Ki ≈ 3 nM) was the first of this class to
demonstrate 5-HT3 receptor binding.89 Quipazine (13) was used as a lead compound to
develop two general series: bicyclic and monocyclic arylpiperazines. Phenylpiperazine
itself binds with low affinity (Ki ≈ 3000 nM) at 5-HT3 receptors.7 The 3-position of
phenylpiperazine was shown to be important for binding as demonstrated by the impro-

13

14

15
Figure 7. The structure of a few arylpiperazine analogs.
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ved affinity of 3-chlorophenylpiperazine (Ki ≈ 62 nM).7 However, the corresponding 3CF3 analog displayed decreased affinity (Ki ≈ 1390 nM).7 The affinity of 3chlorophenylpiperazine

could

be

mimicked

by

its

naphthyl

analog

1-(2-

naphthyl)piperazine (2-NP; 14; Ki ≈ 32 nM).88 Methylation of the terminal piperazine
nitrogen atom of quipazine further increased binding affinity and selectivity (NMQ; 15;
Ki ≈ 2 nM).88 Tricyclic derivatives have also been studied.90-92 Quite a few
arylpiperazines have been shown to bind at 5-HT3 receptors; some have been shown to be
agonists and some have been shown to be antagonists.83 However, none of them have
been shown to be highly selective for 5-HT3 receptors because they also show affinity for
other serotonin receptors93,94 and the serotonin reuptake transporter (SERT).95
The first non-tryptamine, non-arylpiperazine agonist ligand that demonstrated
selectivity for 5-HT3 receptors was phenylbiguanide (PBG; 16; Ki ≈ 1000 nM) (Figure 8);
despite its low affinity, PBG was shown to be more selective than early
arylpiperazines.7,87 PBG is a selective low affinity agonist and arylpiperazines are higher
affinity non-selective agents. Although there was no evidence suggesting that PBG was
binding in the same manner as arylpiperazines, the assumption that they use the same
aromatic site served as the starting point for the investigation of novel analogs of PBG. If
they bind in a similar manner, then it might be possible to use the structure-affinity
relationships (SAFIR) of arylpiperazines to enhance the affinity of the arylbiguanides.
Two novel arylbiguanides were looked at initially, 1-(3-chlorophenyl)biguanide
(mCPBG; 17; Ki ≈ 17 nM) and 1-(2-naphthyl)biguanide (18; Ki ≈ 12 nM).7,93 Both have
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high affinities. mCPBG not only displayed partial agonist characteristics in functional
studies (i.e., rabbit bladder preparation and von Bezold-Jarisch reflex)7 but was shown
that in a competition for binding to 5-HT3 receptors mCPBG inhibited [3H]GR67330 with
100 times higher affinity than 5-HT (1) or PBG (16).96 PBG and mCPBG have been two
of the most widely used 5-HT3 receptor agonists even though they may not penetrate the
BBB.97 Bachy et al.97 found that both PBG and mCPBG displayed poor brain penetration
in mice because they did not displace the binding of [3H]granisetron in an ex vivo
binding experiment. In addition, Rahman et al.9 showed that both possess low
octanol/water partition coefficients. In contrast, Kilpatrick and Rogers98 have shown that
mCPBG displaces [3H]GR65630 in rat entorhinal cortex in an ex vivo binding study.
Moreover, Steward et al.99 have used [3H]mCPBG to label 5-HT3 receptor recognition
sites in rat brain, which would also indicate that mCPBG does cross the BBB. More
selective agonists have since been developed (e.g., 2,3,5-tri-Cl-PBG, Ki = 0.4 nM)100;
however, mCPBG is still commonly used. A wide variety of substituents on the
phenylbiguanide ring have been investigated but will not be discussed here.7,83,101
Using a deconstruction-reconstruction-elaboration approach, the elements needed
for binding of mCPBG (17) at 5-HT3 receptors were evaluated.7,100 In the deconstructionreconstruction-elaboration approach all substituents from a ligand that bind well to a
particular receptor are removed and then the ligand is reconstructed by re-introducing
each of the original substituents individually.102 This approach allows for each substituent
to be evaluated for its effect on binding affinity and/or receptor selectivity.102 The
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resulting ligand is elaborated on to explore new substituents and their role on binding
affinity and/or receptor selectivity.102 During the elaboration process N,N-Dimethylation
of the terminal amine of the biguanide moiety was found to abolish affinity.7 Replacing
the N2 nitrogen atom (Figure 8) of mCPBG with an oxygen atom greatly decreased
affinity.7 Furthermore, removal of the N4 nitrogen atom abolished affinity.7 The N-(2phenylethyl)guanidine analog binds with high affinity (Ki ≈ 40 nM), indicating that the

16

17

18

Figure 8. The structure of phenylbiguanide analogs.

biguanide moiety may not be required for binding.7 Upon further deconstruction of
mCPBG, the biguanide function was shortened to a guanidine yielding a new class of 5HT3 receptor agonists—the phenylguanidines (PG). The first member of this class was 3chlorophenylguanidine (mCPG; MD-354; 2; Ki ≈ 35 nM) which has been shown to also
be an agonist in the von Bezold-Jarisch assay and the rabbit bladder prepartion.7 Various
aryl substituents have been investigated by our laboratory (Table 2).7,100 Parallel changes
in the structures of PBGs and PGs led to parallel shifts in affinity suggesting that the two
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series bind in a similar manner.100 For example, removal of the 3-chloro group to give the
parent PG (27) reduced affinity (Ki ≈ 2340 nM); likewise removal of the 3-Cl group from
mCPBG (17) to generate PBG (16) decreased affinity (Ki ≈ 1000 nM). Positional changes
of the chloro group (i.e., 2-Cl and 4-Cl) also decreased affinity (19-20, 28-29), but not as
Table 2. Binding affinities of several arylbiguanides and arylguanidines.7,8,101

16
17
19
20
21
22
23
24
25
26

Ki (nM)
R
≈1,000.0
H
17.0
3-Cl
62.0
2-Cl
200.0
4-Cl
220.0
3-NO2
780.0
3-CH3
700.0
3-CF3
12.0 3,4-di-Cl
1.8 3,5-di-Cl
2.7 3,4,5-tri-Cl

27
2
28
29
30
31
32
33
34
35

Ki (nM)
2,340.0
35.0
190.0
320.0
85.0
6,520.0
5,700.0
3.1
5.0
0.7

dramatically as removal of the chloro group. Replacing the 3-chloro group with an
electron-donating group (i.e., 3-methyl; 22, 31) or a better electron-withdrawing group
(i.e., 3-CF3: 23, 32) resulted in a decrease in affinity as shown in Table 2. Replacing the
3-chloro group with the electron-withdrawing group 3-NO2 (i.e., 21, 30) resulted in
slightly decreased affinity. Multiple chloro groups (i.e., 3,4-di-Cl, 3,5-di-Cl, 3,4,5-tri-Cl)
increased affinity (24-26, 33-35).
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Based on the binding profile of several arylguanidines at 5-HT3 receptors a
pharmacophore model was developed. A few pharmacophore models for agonists and
partial agonists have been developed but these were for other classes of 5-HT3 receptor
ligands.103,104 Dukat developed the current working pharmacophore for arylguanidines
and arylbiguanides (Figure 9).83 The three main components of the working
pharmacophore for arylguanidines and arylbiguanides are i) an aromatic ring, ii) an
adjacent nitrogen atom, N1, to the ring, and iii) a terminal amine; with distances

Figure 9. Dukat’s pharmacophore for the binding of arylguanidines and arylbiguanides at
5-HT3 receptors. 83
between the aromatic ring centroid and the adjacent nitrogen 2.7 Å (a) and the distance
between the centroid and the terminal amine between 4.5 and 4.9 Å (b). Substitution at
the meta and para positions are tolerated and can enhance affinity depending on their
lipophilic and electronic character. Steric bulk does not seem to be tolerated near the N1
nitrogen atom.
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5. Antagonists

In the late 1970s, Fozard reported metoclopramide and cocaine (which was also
reported by Gaddum and Picarelli)2 to be weak antagonists of the 5-HT-M receptor.105 In
1983, bemesetron (MDL-72222; 9) was first synthesized as an analog of cocaine.106
Shortly after in 1985, workers at Sandoz identified tropisetron (ICS 205-930; 5) as a 5HT3 receptor antagonist.84 Since then, several hundred other compounds have been
developed as 5-HT3 receptor antagonists with a wide range of classifications.107-109 The
two overarching classes are the benzamides or benzoate esters, and 6,5-heteroaromatics.
Benzoate esters (i.e., bemesetron; 9; Figure 10) and benzamides (i.e., zacopride;
37; Figure 10) were developed, as mentioned earlier, as analogs of cocaine.105 Starting

with benzoate esters, the endo isomer was found to be more active than the exo isomer.106
Substitutions at the 3-position were favored over the 4-position, and a 3,5-di substituted
analog (e.g., bemesetron; 9; pA2 = 9.3 rabbit heart) was found to be more active than just
the 3-substituted analog (as reviewed by King).108 However, the 3,5-dichlorobenzamide
analog was reported to be more potent than the 3,5-dichlorobenzoate analog.110
Expanding further, it was found that 2-OCH3, and 4-NH2 groups increased potency
significantly leading to zacopride (37; Bezold-Jarish, ID50 0.7 μg/kg i.v.) and renzapride
(38) (Figure 9) (as reviewed by King).108
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Figure 10. The structure of a few benzoate ester and benzamide 5-HT3 receptor
antagonists.

The largest class, 6,5-heteroaromatics, includes the carbazole ondansetron (3; Ki ≈
7.59-7.76 nM), the indole tropisetron (5; Ki ≈ 3.80-5.50 nM) and the indazole granisetron
(4; Ki ≈ 2.34-3.24 nM).111 Richardson et al. identified tropisetron (5) as the first highly
potent 5-HT3 receptor antagonist that includes an indole ring and an endo(tropane) side
chain.84 Variations on the side chain led to the development of dolasetron (6).108
Modifications of the indole ring to indazole produced compounds similar to granisetron
(4).108 In the indazole series, the 1-CH3 analog showed increased potency unlike with the
indole series.108 In the indolylpropanone series, substitutions of the terminal amine with
–N(CH3)2 (pA2 = 6.5, rat vagus nerve) and –imidazole (pA2 = 7.61, rat vagus nerve) were
shown to be active; while –pyrazole and –triazole were inactive.112 Substitutions at the 2and 4-position of the imidazole of an imidazolyl indolylpropanone were investigated to
prevent interactions with Cytochrome P450.112 The methyl group at the 2-position of the
imidzole was shown to be the most potent N-linked imidazolyl indolylpropanone
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investigated so far in the Bezold-Jarisch assay.112 Conformationally constraining the
carbonyl to the indole ring to form an N-linked imidazolylmethyl tetrahydrocarbazolone
provided a more potent analog (i.e., ondansetron; 3; pA2 = 8.6 rat vagus nerve) than the
unconstrained analog (i.e., the 2-CH3 imidazolyl indolylpropanone analog; pA2 = 8.0 rat
vagus nerve).112 Ondansetron (3) had enhanced oral activity (ED50 = 7 μg/kg, po) in the
rat and a long duration of action (>3 h at 30 μg/kg, iv) in the Bezold-Jarisch assay in the
cat.112 Unusually, both enantiomers of ondansetron had similar activity in vitro ((S)enantiomer pA2 = 8.55; (R)-enantiomer pA2 = 8.95, rat vagus nerve).112 In determining
whether a N-linked imidazole was preferred, several C-linked imidazole analogs were
investigated (i.e., GR65630; pA2 = 9.9; alosetron; 8; pA2 = 10.2, rat vagus nerve).112 This
class is of particular interest since it includes all but one of the clinically available and
highly selective antagonists for 5-HT3 receptors (Figure 5). The remaining clinically
available agent is a 6,6,6-heteroaromatic compound (i.e., palonosetron; 7) (Figure 5).
6. Quantitative Structure-Activity Relationships

The concept of quantitative structure-activity relationships (QSAR) was
developed by Hansch on the basis that biological activity is a function of chemical
structure.113,114 By structure, Hansch considered the lipophilic, electronic, and steric
effects of a molecule. A Hansch analysis is performed by inspecting the linear regression
of the biological activity (e.g., pKi) and various structural parameters (e.g., σ, π, MR, L,
B1, B5) (Table 3). Examples of lipophilic parameters include partition coefficients (log
P) and the substituent’s hydrophobicity constant (e.g., π).115 Electronic parameters
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include Hammet constants (i.e., σm and σp),115 dissociation constants,115 and dipole
moments.116 Steric parameters include Taft’s substituent constant (Es),117 Verloop
parameters (e.g., L, B1, B5),118,119 and molar refraction (MR).115 Molar refraction and
complete molar refraction (CMR) can also be considered a polarizability parameter along
with the number of valence electrons (NVE),120 the parachor constant (Pc),121 and the
polarizability values.120
Table 3. Definition of various Hansch analysis parameters.

Parameter
π
σm
L
B1
B5
MR
Vol
NVE
CMR
MV
Pc
Polarizability
a

Definition
Hydrophobicity constanta
Hammett constant, electronica
Length between substituent and parent compoundb
Shortest width of the substituentb
Longest width of the substituentc
Molar refraction of the substituent;a
  n 2  1 /  n 2  2   *  MW /  


Solvent accessible volumed
Number of valence electrons;e
H = 1; C = 4; N = 5; O = 6, Halogen = 7
Complete molar refractionf
Molar volume;g
MW / 
Parachor based on surface tension and MV;g
 1/4  MW /  
Polarizability of the compoundg

Hansch, et al.115
Verloop, et al. 118
c
Tipker and Verloop119
d
Measured using Chimera
e
Verma et al.120
f
Calculated using ChemDraw
g
Calculated using ChemSketch
b
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Comparative molecular field analysis (CoMFA) is another method of QSAR
analysis. A 2001 study by Dukat et al. on the binding of arylguanidines and
arylbiguanides was conducted using 33 compounds spanning a 10,000-fold Ki range.100
The relationship between parallel substituted arylguanidines and arylbiguanides was
nearly linear (i.e., r = 0.932, n = 9), so it was considered acceptable to use a combination
of these two classes of agents in the same study.100 The results showed that binding to 5HT3 receptors was sensitive to the electronic character of the 3-position and that the
lipophilic character of the 4-positon might also contribute to binding. However, these
compounds are not co-planar making the two meta-positions different; with a sample size
this small (n = 33) the investigators were unable to determine which meta-position is
involved in binding.100 In CoMFA studies the q2 value is the predictability of a model
based on cross-validation,122 and a good q2 value is considered to be greater than 0.6.123
The r2 value is the fit of the binding affinities; the squared correlation coefficient is
usually high when the ligands are well aligned. The q2 value for this CoMFA study was
0.584 and the r2 value was 0.851.100 Based on the results 79.5% steric and 20.5%
electronic effects impacted the binding at 5-HT3 receptors.100
In 2003, Glennon et al.124 performed a QSAR study on the binding of
arylguanidines and arylbiguanides at 5-HT3 receptors. As part of this study the authors
found no correlation between affinity and π3, but that there is some relationship between
affinity and σm for the 3-monosubstituted arylguanidines.124 As for the 4-monosubstituted
arylguanidines it was found to be the opposite of the 3-monosubstituted compounds;
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there was a relationship between affinity and the hydrophobicity constant π4, but not
between affinity and the electronic constant σp.124 Overall, the electron withdrawing
nature of the 3-position substituent and the lipophilic nature of the 4-position substituent
contribute to the affinity of arylguanidines.124 In addition, the polarizability of the
arylguanidines seems to play a role in the affinity of these ligands for 5-HT3 receptors.124
7. Behavioral Assays for Antidepressants

Because a portion of the work to be described herein involves the possible
antidepressant actions of 5-HT3 receptor ligands, it is appropriate to describe a few assays
that have been used previously to evaluate possible antidepressant activity and are
applicable to the current investigation.
In the late 1970’s Porsolt developed a behavioral assay for the screening of
antidepressants—the forced swimming test (FST).125,126 This test is based on the
observation that a mouse placed in water swims (perceivably to escape) then alternates to
a period of immobility. Antidepressants decrease the amount of time the mouse spends
immobile and increase the amount of time the mouse spends swimming. However, there
are a number of issues with the FST that make it less than ideal. Since the water is
approximately at room temperature (23-25 °C) and the mouse’s body is quite small,
hypothermia can occur.127 With this test, there is an inherent need for the animals to be
able to swim; some genetically altered mice have decreased motor function and cannot
swim.128 The FST has also been shown to be ineffective in certain strains of mice (i.e.,
NMRI, C57BL/6J, and DBA2) for almost all known types of antidepressants.129 In
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addition, the FST has been shown to display inconsistent results regarding selective
serotonin reuptake inhibitors (SSRIs).130
The mouse tail suspension test (TST) is a behavioral assay developed by Steru et
al.131 based on the observation that a mouse suspended by its tail will exhibit two types of
alternating behaviors: a waiting phase characterized by immobility or passive swaying,
and a searching phase characterized by running motions, body jerks, and body torsions in
which the mouse attempts to catch its tail. This test, similar to the FST, is based on
changes in immobility time.126 A mouse given an antidepressant will exhibit lower
immobility times than a mouse given saline; the mouse will spend more time in the
searching phase. With the TST, the mice become immobile more quickly over the course
of the test; in the FST, immobility generally occurs in the last half of the test, but in the
TST immobility can occur at any point.128 However, immobility periods are shorter in
duration over the course of the TST.128 Occasionally, false positives are encountered if
the drug given causes an overall increase in motor activity and which can be interpreted
as decreased immobility time (see below for greater detail; “Locomotor activity”). The
TST also is more sensitive to lower doses of drugs.131
In the few studies reported to date, the 5-HT3 receptor antagonists ondansetron (3)
and bemesetron (9) have been shown to be active in these types of behavioral tests for
antidepressants leading investigators to believe that 5-HT3 receptors may be involved in
depression.13,15,17 However, in two of the four FST assays, ondansetron was found to be
inactive (Table 4). Bemesetron has only been examined in the TST. In one investigation,
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the 5-HT3 receptor agonist, SR 57227A, was studied both in mouse and rat FST and was
found to be effective at high doses.14 Table 4 summarizes the 5-HT3 receptor ligands that
have been tested for antidepressant activity in rodents.
8. Locomotor Activity Assay

The TST and FST are only indicative of antidepressant activity. Decreased
immobility time may also occur when the overall movements are increased. This increase
in generalized motion can give a false positive result in the TST and FST. Using a
locomotor activity assay, the overall motion can be investigated in relation to vehicle
(i.e., saline). This test is conducted in square, transparent chambers surrounded by
infrared photo detectors. These photo detectors are located near the floor of the chamber
(~ 1.75 cm above the floor), as well as, ~ 6.5 cm above the floor of the chamber. Using
the breaks in the infrared beams, a computer program identifies precisely where the
mouse is located in the chamber and the type of motion. If the compound in question has
increased general motion relative to the vehicle, it may indicate that the decreased
immobility times of the FST or TST are not because of an antidepressive effect but to an
overall increase in movement.

Sprague-Dawley
Sprague-Dawley

Rat
Rat

FST

FST

FST

FST

TST

FST

FST

FST

TST

FST

Assay

Intraperitoneal (ip), Subcutaneous (sc), Per os (po).

ICR

Mice

a

ICR

Swiss

Mice

Mice

Albino

Mice

SR 57227A

Swiss

Mice

C57BL/6J/Han

Swiss

Mice

Mice

Swiss

Strain

Mice

Species

Bemesetron

Ondansetron

Compound

po

ip

Yes

Yes

Yes

Yes

ip
po

Yes

No

ip
sc

Yes

No

ip
ip

Yes

Yes

Antidepressant
Activity

ip

ip

Route of
Administrationa

Table 4. 5-HT3 receptor ligands assessed in antidepressant assays.

1-30 mg/kg
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1-30 mg/kg
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0.3-3 mg/kg
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0.01 μg/kg

0.005-1000 μg/kg

0.005-1000 μg/kg
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10-30 mg/kg

10-30 mg/kg

10-30 mg/kg
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14

14

14
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III. Specific Aims and Rationale

The arylguanidine series of 5-HT3 receptor ligands has been examined by Dukat
and co-workers9,100,124 in the past to determine the type of substituents favored for
binding. MD-354 (2) is a bi-planar molecule where the guanidine function is skewed
relative to the aromatic ring; therefore, the meta-positions are non-equivalent. Several
series of compounds will be synthesized to investigate the role of meta-position
substituents in binding. One series will investigate the size of the substituent while
another will investigate which meta-position is important.
Based on prior QSAR studies (see Background), steric and electronic effects at
the 3-position, but not lipophilic effects at the 3-position, can influence the fit (i.e.,
affinity) of the ligand in the 5-HT3 receptor binding pocket. These previous studies
indicated meta-position substituents are important for binding. Since the 3-Cl analog
(MD-354, 2; Ki = 32 nM), which bears an electron-withdrawing substituent, binds with
high affinity, but analogs with electron-donating groups, as seen with the 3-CH3 (31; Ki =
6520 nM) and 3-OCH3 (39; Ki = 1600 nM) analogs, bind with reduced affinity, it might
be concluded that electronic effects play a significant role.124 However, the 3-CF3 analog
(32; Ki = 5700 nM), an analog containing a stronger electron-withdrawing substituent
than a chloro group, binds with reduced affinity relative to MD-354 (2) which may
indicate that the possibility of steric interactions or bulk limitation.124 It may be the size
33
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or the shape of the –CF3 group that detracts from binding. The –Cl substituent has a
spherical shape whereas a –CF3 substituent does not; its shape may not be tolerated by
the receptor. The –CF3 group occupies a slightly larger volume of space than the –Cl
group (Table 5) which may also not be tolerated by the receptor. One of the aims of this
project is to synthesize other 3-halogenated analogs of MD-354 (2) and to examine their
electronic and steric effects on binding affinity. Fluoro, bromo, and iodo groups are
electron-withdrawing groups and together with the –Cl and–CF3 groups, provide a range
of electron-withdrawing substituents of graded size and relatively similar electronwithdrawing capability (Table 5). Examination of the –F, –Br, and –I analogs (i.e., 4244), in comparison with the –Cl (2) and –CF3 (32) compounds (as well as with the parent

unsubstituted molecule 27), will provide information about the importance of the steric
and electronic contribution of 3-position substituents to affinity. With the halogen
analogs, substituent size can be varied while keeping shape and electronic character
relatively constant (Figure 11). Therefore, compounds 42-44 will be synthesized and
examined for comparison with 2, 27, and 32.
A Hansch analysis of 3-substituted analogs might assist in determining which
structural features may be important for binding at 5-HT3 receptors. The relationship
between pKi and various parameters (i.e., π, σ, L, B1, B5, MR, complete molar refraction
(CMR), volume, molar volume (MV), NVE, Pc, and polarizability) will be investigated
through a Hansch analysis. Correlation coefficients from linear regression analysis would
indicate the possible significance of those parameters.
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Figure 11. Superimposition of the Van der Waals surface of 3-CF3 (cyan), 3-I (purple),
3-Br (orange), 3-Cl (pink), 3-F (green), and 3-H (black) PGs (left). Superimposition of
the Van der Waals surface of 3-CF3 (cyan) and 3-Cl (pink) PGs (right.)
Table 5. Electronic, lipophilic, and steric effects of 3-substituted arylguanidines.
NH2

N

NH2

R

27
2
30
31
32
39
40
41
42
43
44
a

R
H
Cl
NO2
CH3
CF3
OCH3
CN
OH
F
Br
I

a

π
0.00
0.71
-0.28
0.56
0.88
-0.02
-0.57
-0.67
0.14
0.86
1.12

σa
0.00
0.37
0.71
-0.07
0.43
0.12
0.56
0.12
0.34
0.35
0.35

Volumeb
121.7
144.8
143.9
138.3
150.5
145.6
139.2
126.8
125.6
165.6
197.7

π and σ values as reported by Hansch et al.115
Volume is the solvent accessible volume measured using Chimera.
c
Results from a previous study.7,100
b

Ki (nM)c
2,340
35
85
6,520
5,700
1,600
123
2020
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Since MD-354 is bi-planar, it can exist in multiple conformations. In two of the
possible rotamers, the substitutents can reside at either one of two meta-positions (i.e., the
3- or 5-positions) (Figure 12). By constraining the guanidine function, it can be
determined which of the two meta-positions is more important for binding (Figure 13).
Constraining the guanidine to a five-membered ring (e.g., as with 45) sharply decreased
binding affinity (Ki = 725 nM) relative to MD-354 (2; Ki = 35 nM).9 Previous literature
reported

the

synthesis

of

what

was

thought

to

be

2-amino-7-chloro-3,4-

dihydroquinazoline (46);9 this was later shown to actually be 2-amino-6-chloro-3,4dihydroquinazoline (47).132 In addition, 2-amino-5-chloro-3,4-dihydroquinazoline (48)
has been synthesized previously.133 Since 2-amino-7-chloro-3,4-dihydroquinazoline (46)
has not been synthesized previously, it will be targeted for synthesis by this investigation
to complete the series.

Figure 12. Representation of a rotatable bond in MD-354 (2).

Increasing the ring size constraining the guanidine allows for an increase in the
angle of the aromatic and guanidine planes, so the seven-membered constrained analog
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45

46 7-Cl
47 6-Cl
48 5-Cl

49

Figure 13. Structure of conformationally-constrained analogs of MD-354.

(2-amino-8-chloro-1,3-benzodiazepine; 49; Figure 13) will also be synthesized. In
addition, the different ring sizes allow for small adjustments in the centroid-to-amine
distance which has been shown to be important for 5-HT3 receptor binding (Figure 9)
(MD-354 centroid-to-amine distance was previously calculated to range from 3.7 to 4.9
Å; 45 centroid-to-amine distance was previously calculated to be 4.5 Å; 46-48 centroidto-amine distance was previously calculated to be 4.9 Å).9 For the purpose of this study,
the ligands were built in Sybyl 7.3, given new charges and geometries calculated with
molecular orbital package (MOPAC), and the aromatic centroid to primary amine
distances were measured (Table 6). The aromatic centroid to primary amine (N2)
distance of MD-354 (2) is calculated to be 5.1 Å. The aromatic centroid to primary amine
distance of 45 is calculated to be 4.5 Å. The aromatic centroid to primary amine distance
for 46-48 is calculated to be 5.0 Å and the aromatic centroid to primary amine distance of
49 is calculated to be 5.1 Å. Other methods of investigating the skewness of these

constrained analogs are to examine the height above the plane, the plane angle and the
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torsion angle (Table 6). The height above the plane for the nitrogen atoms indicate how
much out of the plane of the aromatic ring the guanidine is. Since the guanidine function
is in a separate plane from the aromatic ring the angle of these planes can also be
calculated. The torsion angle is the twist of the molecule while going from the guanidine
portion to the aromatic ring.
Table 6. Measurements of biplanarity of MD-354 and its constrained analogs.

Compound
2
45
46 - 48
49

Amine height
above plane
0.21683 Ǻ
0.00327 Ǻ
0.16662 Ǻ
0.24949 Ǻ

Aromatic
centroid to
primary amine
distance
5.122 Ǻ
4.537 Ǻ
5.042 Ǻ
5.133 Ǻ

Plane angle
34.91°
0.06°
8.48°
7.13°

Torsion angle
149.9°
180.0°
189.9°
184.4°

Another goal of this work will be to confirm whether or not 5-HT3 receptor
ligands produce an antidepressant effect in animals. Depression has a life-time prevalence
of 17% in the United States.134 Current treatments for depression are fully effective for
30% of patients.135 The antidepressants currently available (i.e., tricyclic antidepressants
(TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine
reuptake inhibitors (SNRIs)) have a long onset of action (usually two or more
weeks).136,137 These drawbacks indicate a need for a new understanding on how to treat
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depression. Although studies are scant, two 5-HT3 receptor antagonists (i.e., ondansetron
and bemesetron) and the 5-HT3 receptor agonist (i.e., SR 57227A) have been shown to
behave as potential antidepressants in animal studies (Table 4). If 5-HT3 receptors play a
role in depression then different structural classes of 5-HT3 receptor agents or different
receptor interactions may be able to elicit the same response. To determine if the novel
series of quinazoline ligands behaves in the same manner, several analogs will be tested
using the mouse tail suspension test for antidepressant activity. The parent compound,
MD-354 (2), will also be tested. Tricyclic antidepressants (i.e., desipramine and
imipramine), an SSRI (i.e., fluoxetine), and a 5-HT3 receptor antagonist (i.e.,
ondansetron) will be used as controls. Statistical analysis will be performed to determine
the statistical significance of any decreases in immobility time relative to saline using a
one-way analysis of variance (ANOVA) test. Overall locomotor activity will be
examined at any doses of those drugs that display significantly lower immobility times
than saline to determine if the effect is because of hyperactivity or not.
A recurring issue with most 5-HT3 receptor ligands is their inability to cross the
BBB. Compounds with log P values ranging from 1.5 to 2.5 generally can penetrate the
BBB.138 MD-354 (2), PG (27), 3,4,5-tri-Cl-PG (35) and mCPBG (17) have been shown to
have log P values of -0.64, -1.32, 1.16, and -0.38, respectively, by the shake-flask
method of measuring the concentration of drug in the aqueous layer of an aqueous 1octanol solution, which would indicate that these compounds should not be able to
readily cross the BBB.9 Supporting this, Bachy et al.91 showed that PBG and mCPBG
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were unable to displace [3H]granisetron in an ex vivo study indicating that arylbiguanides
probably do not cross the BBB. In contrast, Kilpatrick and Rogers98 showed that mCPBG
was able to displace [3H]GR65630 in rat entorhinal cortex ex vivo and Steward et al.99
used [3H]mCPBG to label 5-HT3 receptor recognition sites in the rat brain. These last two
studies indicate that the arylbiguanide mCPBG does cross the BBB. Because the data are
controversial, a new method is needed to determine if arylguanidines and arylbiguanides
cross the BBB. Using ChemDraw to predict log P values, the predicted log P value for
mCPBG is 1.28, which indicates that it is slightly too low for mCPBG to easily cross the
BBB, supporting the shake-flask data. Whereas, the predicted log P value for MD-354 is
1.43, which is closer to the threshold for easily crossing the BBB. Both of these predicted
values are much higher than the shake-flask data. The determination of log P values using
the shake-flask method is time consuming, requires a large amount of sample, and is
subject to errors (i.e., sample impurities, inability to detect the sample, dissociation,
decomposition, and stable emulsion formation).139 In addition, very high and very low
partition compounds cannot be measured through the shake flask method.139
Another method of determining the log P value is through the relative retention
times using high performance liquid chromatography (HPLC) which requires much
smaller quantities of sample and provides for better detection. The retention times of
several compounds (i.e., imidazole, acetanilide, benzophenone, naphthalene, and
diphenylamine) are determined relative to the retention time of uracil for various
concentrations of aqueous acetonitrile. Values for the log of the capacity factor ( k ' ) are
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calculated for each of these compounds at varying concentrations of acetonitrile and
water ( log k '  log  tR  t0  t0  ).140-142 For each compound, a plot of log k ' versus the
concentration of acetonitrile is used to calculate the log kw' (i.e., the log of the capacity
factor in 100% water).140-142 These log kw' values can be plotted against experimental log
P values from the literature to construct a standard curve. By identifying the log kw' value
of unknown compounds the log P value can be determined using the standard curve
obtained from the known compounds. This method will be implemented to determine the
log P values of mCPBG and several arylguanidines.
Different homology models of the h5-HT3A receptor can be built through various
modes of construction. Each program uses different methods for developing models.
Using the Biopolymer package of Sybyl, residues of a template can be mutated to the
sequence of the target receptor. This is followed by optimizing the side-chain orientation
with SCRWL. Another method is to use an alignment of the template and the sequence of
the target, and allowing the program Modeller to generate multiple models at one time.
By using docking programs (e.g., GOLD and AutoDock) and different standards, the
models can be validated by mutagenesis data. Since arylguanidines have not been
generally studied as a class of 5-HT3 receptor ligands, their possible binding modes have
yet to be determined. In the present study, 5-HT3 receptor models will be constructed and
docking studies performed with both GOLD and AutoDock. Based on the docking poses
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of MD-354 and 5-HT, new ligands might be developed which encompass structural
features that are beneficial for each.
To summarize, the specific aims of the present work are:
a) to synthesize various halogen-substituted arylguanidines,
b) to determine the structural features important for binding through a Hansch
analysis,
c) to synthesize conformationally constrained arylguanidines,
d) to evaluate the possible antidepressant activity of selected agents through the
mouse tail suspension test,
e) to determine the log P value of various arylguanidines, and
f) to construct and validate a homology model of the 5-HT3 receptor.
Overall, the aims of these studies are the rational design and synthesis of novel 5HT3 receptor agents that enter the brain, and an initiation of their pharmacological action.

IV. Results and Discussion
A. Halogen Series
1. Synthesis of N-(3-Fluorophenyl)guanidine Nitrate (42)

N-(3-Fluorophenyl)guanidine nitrate (42), was synthesized in the same manner as
MD-354 (2) (Scheme 1).143 N-(3-Bromophenyl)guanidine nitrate (43) and N(iodophenyl)guanidine nitrate (44) analogs were previously synthesized in our
laboratory132 as nitrate salts and were available for our studies. The hydrochloride salt of
the aniline was allowed to react with cyanamide in ethanol and heated at reflux. The
hydrochloride salt of the arylguanidine was converted to the nitrate salt (i.e., 42) with
ammonium nitrate. The structure was confirmed by IR spectrometry,
spectrometry, and elemental analysis for C, H, N.
Scheme 1.a

a, b

50

42

a

Reagents and conditions: a. H2NCN, EtOH, reflux; b. NH4NO3, H2O.

43

1

H NMR

44
2. Binding Studies

The three new arylguanidine analogs (42-44) were evaluated and MD-354 (2) was
re-evaluated for binding affinity at recombinant mouse 5-HT3A receptors (Table 7) using
[3H]LY 278,584. The –Br (i.e., 43) and –I (i.e., 44) analogs were found to bind with the
highest affinity. MD-354 (2) was found to bind with a somewhat lower affinity than
previously reported for binding affinity at cloned human 5-HT3AB native receptors.7
Based on these results it can be concluded that the size of the electron-withdrawing
substituent possibly plays a role in how well these compounds bind to the 5-HT3 receptor
since compounds with smaller meta-substituents (i.e., –H (27; Ki = 2340 nM) and –F
(42)) bind with decreased affinity and compounds with larger meta-substituents (i.e., –Br
(43) and –I (44)) bind with increased affinity compared to the parent compound, MD-354
(2).
Table 7. Binding affinity of halogen series at the mouse 5-HT3A receptors.
NH2

N

NH2

R

42
2
43
44

R Ki (nM) (SEM)
F
1420 (105)
Cl
166
(16)
Br
81
(10)
I
40
(5)
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This is the reverse of what was expected and suggests that meta-substituents
larger in size than a chloro group are tolerated by the receptor. Since the –CF3 analog
binds with lower affinity at the 5-HT3 receptors than any of the mono-halogenated
analogs, but takes up less volume than –Br and –I it may be concluded that it is the shape
and not necessarily the size of the –CF3 group that interferes with binding. The halogen
substituents are spherical but the –CF3 substituent is not; a more spherical shape might be
more tolerated. It might be noted that for the simple halogenated analogs shown in Table
7, affinity increases as the lipophilicity (i.e., π value; see Table 5) increases. Likewise,
affinity increases as substituent volume (see Table 5) increases. For example, there is a
relationship between pKi and π (r = 0.997, n = 4; Figure 14) as well as with volume (r =
0.920, n = 4; Figure 14). This trend holds if phenylguanidine 27 is included (r = 0.998, n
=5; r = 0.934, n = 5; Figure 14). However, there are too few observations to draw any
reliable conclusions.
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Figure 14. Linear regression plots of pKi versus π (left) and volume (right). The analyses
including the unsubstituted compound 27 are shown in red, excluding the unsubstituted
compound are shown in blue.
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3. Hansch Analysis

A Hansch analysis was performed on the 3-position monosubstituted
arylguanidines to better identify electronic and steric effects that might be influencing
their binding to the 5-HT3 receptor. The analysis was performed on the parameters (i.e.,
π, σ, L, B1, B5, MR, CMR, volume, MV, NVE, Pc, and polarizability) (Table 8) versus
affinity (i.e., pKi). A linear regression analysis (Table 9) of each of these individual
parameters using GraphPad Prism against pKi revealed statistically significant
correlations (p < 0.05) with the electronic factor σ (n = 11, r = 0.730, F = 10.25; eq 2,
Table 9; Figure 15), polarizability (n = 11, r = 0.704, F = 8.86; eq 12, Table 9; Figure
16), solvent accessible volume (n = 11, r = 0.656, F = 6.80; eq 7, Table 9; Figure 16), and
complete molar refraction (CMR) (n = 11, r = 0.670, F = 7.31; eq 9, Table 9; Figure 17).
These linear regression analyses indicate that the electronic effect of the substituent, the
polarizability of the molecule, the solvent accessible volume of the substituent, or the
complete molar refraction of the molecule may play a role in how well the arylguanidines
bind to the 5-HT3 receptor.
Internal correlations between parameters can lead to collinearity. Multicollinearity
may be or is a problem for these compounds with volume and polarizability (r = 0.742, n
= 11), CMR and polarizability (r = 0.757, n = 11), and volume and CMR (r = 0.704, n =
11)—since these three parameters are intercorrelated with each other it is expected that
there is a problem with multicollinearity.

NH2

5.695 -0.67 0.12 2.7 1.4 1.9 2.85
5.484 0.14 0.34 2.7 1.4 1.4 0.92
7.092 0.86 0.39 3.8 2.0 2.0 8.88
7.398 1.12 0.35 4.2 2.2 2.2 13.9

41 OH
42 F
43 Br
44 I

198

166

126

127

139

6.910 -0.57 0.56 4.2 1.6 1.6 6.33

40 CN

151
146

5.613 0.88 0.43 3.3 2.0 2.6 5.02

39 OCH3 5.796 -0.02 0.12 4.0 1.4 3.1 7.87

32 CF3

138

31 CH3

5.186 0.56 -0.07 3.0 1.5 2.0 5.65

144

30 NO2 7.071 -0.28 0.71 3.4 1.7 2.4 7.36

Binding data from Tables 5 and 7.7,100
See Table 4 for description of parameters.

b

a

R

N

NH2

145

122

58

58

58

58

60

64

76

58

68

58

52

5.39 132

4.86 127

4.10 118

4.15 112

4.56 128

4.70 137

4.59 145

4.54 130

4.69 120

4.57 124

4.08 115

367

347

304

310

350

354

358

335

349

333

304

Lb B1b B5b MRb Volb NVEb CMRb MVb Pcb

6.780 0.71 0.37 3.5 1.8 1.8 6.03

σmb

2 Cl

πb

5.631 0.00 0.00 2.1 1.0 1.0 1.03

pKia

27 H

R

20.53

18.51

15.46

15.85

18.10

17.81

17.39

17.26

17.75

17.33

15.51

Polarizabilityb

Table 8. Hansch analysis of the 5-HT3 receptor binding of 3-substituted arylguanidines.
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Table 9. Linear regression analysis results (n = 11).

Equation
pKi =
1
0.1467  0.2599    0.6721 1.642 

r
0.185

2

0.2230  0.06967    1.098  0.4401

0.730

3

2.583  1.381 MR  10.77  8.724 

0.529

4

0.2399  0.4358  L  1.333  2.753

0.181

5

0.3214  0.1425  B1  0.2826  0.9004 

0.601

6

1.085  0.7941 B5  3.850  5.017 

0.414

7

18.07  6.932  volume  32.04  43.80 

0.656

8

0.2806  2.779  NVE  62.49  17.56 

0.034

9

0.3263  0.1207  CMR  2.519  0.7624 

0.670

10

0.1198  4.232  MV  125.5  26.74 

0.009

11

14.82  8.242  Pc  244.3  52.07 

0.514

12

1.334  0.4484  polarizability  9.036  2.833

0.704

0.8

NO2

0.6

CN
CF3

m

0.4
0.2
0.0
-0.2

Cl Br I

F
OH OCH3
5 CH3 H 6

7

8

pKi

Figure 15. Linear regression plot of pKi versus σm (r = 0.730; eq 2; Table 9).
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(top) and pKi versus volume (r = 0.656; eq 7; Table 9) (bottom).
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Figure 17. Linear regression plot of pKi versus CMR (r = 0.670; eq 9; Table 9).

In order to obtain statistically relevant results for each parameter analyzed, data
on at least six compounds are required. Using compounds 2, 27, 30-32, 39-44, there are
only eleven compounds and, therefore, only one variable can be investigated with
statistical significance. Despite lacking statistical rigor, inclusion of a second variable
might provide some clues as to which variables are simultaneously affecting binding
affinity. A multiple linear regression analysis was performed using GraphPad’s InStat
program on σ, volume, CMR, and polarizability versus pKi (Table 10). There is no
internal correlation between volume (r = 0.851, n = 11), CMR (r = 0.855, n = 11), or
polarizability (r = 0.867, n = 11) and σ; since they are independent of each other, any
relationship of σ and the other three parameters may show an actual relationship together
with the binding affinity. There is a good correlation (p < 0.01) with σ and polarizability
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versus pKi (n = 11, r = 0.867, F = 12.05; eq 15, Table 10), σ and volume versus pKi (n =
11, r = 0.851, F = 10.54; eq 16, Table 10), and σ and CMR versus pKi (n = 11, r = 0.855,
F = 10.86; eq14, Table 10). Based on the results of these analyses, the electronwithdrawing nature and the size, polarizability, or volume of the substituent at the 3position impact binding affinity. Since there are multiple linear regression correlations,
the later three parameters are impacting binding affinity and not just one individual
parameter.
Table 10. Multiple linear regression analysis results (n = 11).

Equation
pKi =
13 -2.010CMR + 0.9141polarizability – 0.4960
14 1.749σ + 1.118CMR + 0.6070
15 1.648σ + 0.3036poloarizability + 0.4594
16 1.846σ + 0.01917volume + 2.893
17 -0.005657volume + 0.4817polarizability – 1.320
18 -0.001501volume + 1.578CMR – 0.7439

r
0.757
0.855
0.867
0.851
0.742
0.704

In agreement with Glennon et al.,124 this study has shown with different
compounds that the electronic character at the 3-position is important for binding
arylguanidines to the 5-HT3 receptor. Dukat et al.100 has shown previously that electronic
effects account for nearly 20% and that steric effects account for nearly 80% of binding
of arylguanidines and arylbiguanides at the 5-HT3 receptor. This study is in agreement
with Dukat and co-worker’s100 study as shown by the correlation between σ and binding
affinity and it has been shown that the volume and complete molar refraction (CMR),
both of which can be viewed as steric factors, provide statistically significant correlations
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with binding affinity. In addition, the polarizability of the molecule, as shown by the
polarizability factor and CMR, also display significant correlations. In this study the
volume may be acting as a surrogate for the polarizability or the polarizability as a
surrogate for the volume. One way to examine this possibility would be to synthesize and
include in future analyses a compound with a substituent that has relatively low volume
and relatively high polarizability (e.g., (3-cyclohexylphenyl)guanidine has a substituent
volume of 201.3 and a polarizability of 25.46 or 2-(3-(prop-1-ynyl)phenyl)guanidine has
a substituent volume of 154.1 and a polarizability of 20.92).
4. Log P Analysis

The retention times on a nitrile reversed-phase high performance liquid
chromatography (HPLC) column of uracil, imidazole, acetanilide, benzophenone,
naphthalene, and diphenylamine were determined in triplicate at various concentrations
of aqueous acetonitrile (i.e., 40%, 50%, 60%, 70% acetonitrile). From the retention times
of the above standards relative to uracil (i.e., tR  t0 ; where t R = retention time of the
standard and t 0 = retention time of uracil), the log of the capacity factor (i.e.,

log k '  log  tR  t0  t0  ) was determined for each of the standards. A plot of logk '
versus the concentration of acetonitrile was constructed (shown for benzophenone in
Figure 18) and a linear regression analysis performed. Using the equation for each plot
the lines for each standard could be extrapolated and the log of the capacity factor at 0%
acetonitrile could be determined ( log kw' ). The log kw' values for each of the standards
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(i.e., imidazole, log kw' = -0.88; acetanilide, log kw' = 0.06; benzophenone, log kw' = 1.18;
naphthalene, log kw' = 1.06; and diphenylamine, log kw' = 1.38) were plotted against the
literature shake-flask log P values (log P = -0.08, 1.16, 3.30, 3.18, 3.50; respectively)
giving a standard curve for this particular column (Figure 19). A linear regression
analysis of this data calculated an equation for the line of log P  1.660log kw'  1.285 (r =
0.996, F = 346.4).

% Acetonitrile

0.5
40

50

60

70

80

log k'

0.0

-0.5

-1.0
'
Figure 18. Plot of logk of benzophenone versus concentration of aqueous CH3CN.

The retention times of PG (27), MD-354 (2), 3-FPG (42), 3-BrPG (43), 3-IPG
(44), 3,4,5-tri-Cl-PG (35), and mCPBG (17) were determined at various concentrations of
aqueous acetonitrile (i.e., 55%, 65%, 75% acetonitrile). Based on the retention times
relative to uracil, the log of the capacity factor was calculated for each of the compounds.
The capacity factors were plotted against the concentration of acetonitrile and a linear

54
4

diphenylamine
benzophenone
naphthalene

logP

3
2
1

acetanilide

imidazole
-1.0

-0.5

0.5

1.0

1.5

-1 logk'w

Figure 19. Plot of literature log P values from shake-flask data144 versus log kw' values.

regression analysis was performed (Figure 20). Based on this analysis the line from each
plot could be extrapolated and the capacity factors at 0% acetonitrile (i.e., log kw' ) could
be determined (Table 11). As long as the same general range of concentration of
acetonitrile was used the exact concentrations need not be the same with the standards
and unknowns since the true value of interest is found based on the extrapolation to 0%
acetonitrile—as if the compound was eluted in water only. The logk ' value at 0%
acetonitrile (i.e., log kw' ) cannot actually be determined since running the HPLC column
in pure water is ill-advised since it may destroy the column. Based on the capacity factors
determined for 0% acetonitrile, the log P values for each of these compounds was
calculated based on the standard curve (Table 11).

55
0.6

MD-354 (2)
PG (27)
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Figure 20. Plot of logk ' of various arylguanidines and mCPBG versus concentration of
aqueous CH3CN.
Table 11. Capacity factors ( log kw' ) determined by linear regression and calculated/
determined log P values for the selected arylguanidines and an arylbiguanide.
Actual
Actual
log
P
log P
Predicted
'
a
b
log
k
w
Compound
(shake-flask)
(HPLC)
log P
0.1665 ± 0.0794
0.87
-1.32
1.56
27
0.2945 ± 0.1248
1.43
-0.64
1.77
2
0.2375 ± 0.0681
1.03
-1.68
42
0.4742 ± 0.1059
1.70
-2.07
43
0.5987 ± 0.0832
2.22
-2.28
44
0.9781
±
0.0927
2.54
1.16
2.91
35
0.2479 ± 0.1570
1.28
-0.38
1.70
17
a
b

Predicted using ChemDraw.
Results from a previously published study.9

As mentioned earlier, compounds with log P values ranging from 1.5 to 2.5
should readily penetrate the BBB.138 Based on these results, most of these arylguanidines
should be able to cross the BBB. The results obtained by relative retention times using
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HPLC were consistent with the predicted log P values from ChemDraw (r = 0.957) and
with the previous studies indicating that mCPBG (17) crosses the BBB.98,99 The study by
Bachy et al.97 that indicated mCPBG could not cross the BBB used a different
radioligand (i.e., [3H]granisetron versus [3H]GR65630), a larger dose (i.e., 2 and 10
mg/kg versus 0.1-1.0 mg/kg), a longer time between injection and removal of the brains
(i.e., 30 min versus 5 min), and a different species (i.e., mouse versus rat). Any of these
differences may account for the difference in results between the two laboratories.
Furthermore, given the evidence that mCPBG (17) can penetrate the BBB through ex
vivo inhibition and radioligand binding, it would seem likely that the halogenated
arylguanidines 2, 42, 43, and 44 should also be capable of such. This method of
determining log P values seems to be more accurate when compared to the predicted
values than the shake-flask method.
5. Molecular Modeling

Homology models were constructed by two different methods (i.e, Method A and
Method B). In both cases the models were developed from an alignment between the Nterminal domain of the h5-HT3A sequence and the sequence of three AChBP’s, the Nterminal domain of a nACh receptor α1 subunit bound to α-bungarotoxin, the N-terminal
domains of three different GABAA receptor subunits, the N-terminal domains of two
different GABAC receptor subunits, the N-terminal domain of two different glycine
receptor subunits, and the N-terminal domain of the mouse 5-HT3A receptor. This
alignment was performed using ClustalX to identify conserved residues within the
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different LGICs; specifically W90, W183, Y234, and the two cysteines forming the Cysloop.
Method A. Using Sybyl’s (version 7.3) Biopolymer package, the α1 subunit of a
nACh receptor (PDB 2qc1)42 was mutated to the sequence of the h5-HT3A receptor using
the conserved residue alignment to identify where insertions and deletions were needed.
This single subunit was minimized using the Amber force field and Amber charges. The
program, SCWRL, was used to optimize side chain orientations. ProCheck was run on
the single subunit to create a Ramachandran plot (Figure 21) to identify amino acid
residues in most favored (red field), additionally allowed (dark yellow), generously
allowed (lighter yellow), and disallowed (white) regions. The Ramachandran plot
indicated that 86.8% of amino acid residues were in the most favored regions, 12.6% of
residues were in the additionally allowed regions, and only 0.5% of residues were in the
disallowed regions. The one amino acid shown in the disallowed region is facing into the
pore and does not interact with the binding pocket so it has no impact on the docking.
Using the backbone of an AChBP (PDB 1i9b)38 for orientation in space of two
protomers, since it is a pentameric structure, a dimer of the h5-HT3A protomer was
constructed.
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Figure 21. Ramachadran plot of a single subunit of the h5-HT3A receptor model
developed using Sybyl's Biopolymer package (Method A).

The ligand 5-HT (1) was built in Sybyl 7.3 and given AM1-BCC charges and
geometries from MOPAC. AM1-BCC charges are quantum mechanical charges that have
bond correction charges (BCC) that allow for accurate charges of small molecules within
the Amber force field. Using Gold 3.1, 5-HT was docked with 20 genetic algorithm runs
in a 15 Å sphere around W183 to the interface between the two protomers. The proposed
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binding mode of 5-HT (Figure 22) was consistent with the literature as the aliphatic
amine is situated in the binding pocket in a way that it is directed towards the aromatic
rings of W183 and Y234 and possibily capable of forming the cation-π bond as reported
in the literature.101,145,146

Figure 22. Proposed binding mode of serotonin (5-HT; 1) in the h5-HT3A receptor
model developed using Sybyl's Biopolymer package (Method A). 5-HT (1) is in magenta
and the side chains of residues within 5 Å of the ligand are shown.

Since the proposed binding mode of 5-HT is relatively similar to that in the
literature,101,145,146 MD-354 (2) was built and docked to the receptor model in the same
manner as 5-HT (Figure 23). The proposed binding mode of MD-354 is similar to 5-HT
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in that the guanidine portion of MD-354 overlaps with the aliphatic amine of 5-HT and is
possibly interacting with W183, Y234, and Y143.

Figure 23. Proposed binding mode of MD-354 (2) to the h5-HT3A receptor using
Sybyl's Biopolymer package (Method A). MD-354 (2) is in cyan and the side chains of
residues within 5 Å of the ligand are shown.
The overlap of MD-354 (2) and 5-HT (1) is depicted in Figure 24; based on these
proposed binding modes to this model, a new ligand was designed taking into account
features both from 5-HT and MD-354. From the overlap of 5-HT and MD-354, it appears
that the addition of a hydroxyl group to the aromatic ring of MD-354 in the 4-position
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would enhance binding (Figure 24). The hydroxyl group of this designed ligand may be
able to interact with Y153.

51
Figure 24. Overlap of 5-HT (1) and MD-354 (2) from the proposed binding modes to the
h5-HT3A receptor developed using Sybyl's Biopolymer package (Method A) (left). The
designed ligand N-(3-chloro-4-hydroxyphenyl)guanidine (right).

Method B. The homology model constructed through Sybyl (Method A) is crude
and rigid, so another method for developing a homology model was explored. An
alignment of AChBP (PDB 1i9b)38, α1 nACh (2qc1)42, and h5-HT3A based on the
conserved residue alignment was used to create ten initial pentameric models from five
separate random seeds using the program Modeller 9.3. The program then generated ten
loop models from each of the initial models, to create a total of 100 unique models. These
models were given Kollman charges then minimized using NAMD, first with the
backbone constrained then with the backbone unconstrained. Using AutoDock4, the
ligand 5-HT (1), with the charges and geometries generated by MOPAC, was docked to
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each of the five interfaces of each of the models with 20 genetic algorithm runs in a 40 Å
x 40 Å x 40 Å region around the C-loop (Figure 25). Based on poses consistent with the

Figure 25. Proposed binding mode of 5-HT (1) in the h5-HT3A receptor agonist model
developed using Modeller (Method B). 5-HT (1) is in magenta and the side chains of
residues within 5 Å of the ligand are shown.

literature for 5-HT145,146 and the scoring function of AutoDock, one model was identified
as the best model for agonists. ProCheck generated a Ramachandran plot in which 67.8%
of residues were in most favored regions, 24.1% were in additionally allowed regions,
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4.5% were in generously allowed regions, and 3.6% were in disallowed regions (Figure
26). Since multiple loop models were made by slight energy adjustments, the side chain
conformations were not optimized using SCWRL; thus, there are more residues in the
generously allowed and disallowed regions than with the model developed with Sybyl’s
Biopolymer package (i.e., Method A).

Figure 26. Ramachadran plot of the h5-HT3A receptor agonist model developed using
Modeller (Method B).
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Serotonin’s indole ring is perpendicular to W90 and the aliphatic amine is situated
between Y234 and W183 forming a possible cation-π bond. This pose is consistent with
poses proposed by Reeves et al.146 The indole amine is in close proximity to the hydroxyl
group of Y153 and may form a H-bond.
Since this model was validated by docking 5-HT, MD-354 (2) was built and
docked in the same manner as 5-HT. In the model, MD-354 docks in a manner in which
the aromatic rings of 5-HT and MD-354 are in the same region of the binding pocket as
are the aliphatic amine of 5-HT and the guanidine of MD-354 (Figure 27). The guanidine
portion of MD-354 presumably forms a cation-π bond with W183 and Y234. The
aromatic ring portion of MD-354 also may form a π-π interaction with Y153. However,
the designed ligand (i.e., 51) from the model developed using Method A (Figure 24) is no
longer valid. The overlap using the model developed using Method B indicates a slightly
different overlap of MD-354 and 5-HT. In the model developed using Method B, the
overlap is such that the –OH group from 5-HT overlaps with the open meta-position of
MD-354.
The newly synthesized halogen analogs were built and docked to this model
following the same parameters. MD-354 (2), 3-BrPG (43), 3-IPG (44) overlapped very
well; however, the aromatic ring and guanidine portion of 3-FPG (42) overlapped with
the other halogenated analogs but the fluoro substituent was situated on the opposite side
of the ring (Figure 28). This slight change may explain why 42 binds with decreased
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affinity relative to MD-354, 3-BrPG, and 3-IPG. In fact, 3-FPG binds more closely to 5HT, and both have lower binding affinities than MD-354, 3-BrPG, and 3-IPG.

Figure 27. Proposed binding mode of MD-354 (2) to the h5-HT3A receptor agonist
model developed using Modeller (Method B). MD-354 is shown in cyan and the side
chains of residues within 5 Å of the ligand are shown.
The fluoro substituent affects the aromatic ring system more than the other
halogen substituents. It is very electronegative and has orbitals similar in size to those of
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Figure 28. Proposed binding mode of MD-354 (cyan), 3-FPG (red), 3-BrPG (blue), 3IPG (yellow) to the h5-HT3A receptor agonist model developed using Modeller (Method
B).
carbon.147 These two factors make the C—F bond the most energetic bond in which
carbon can participate.147 Because of the difference in electronegativity, the dipole
moment that is created may contribute to the compound’s ability to engage in
intermolecular interactions since the physical properties and chemical reactivities are
greatly affected. In addition, it has been shown through X-ray crystal structure data that
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the fluoro group is actually closer in size sterically to an oxygen atom than a hydrogen
atom.148 The 3-OH substituted phenylguanidine (41; Ki = 2020 nM)100 has been shown to
have binding affinity slightly lower than 3-FPG (42; Ki = 1420 nM). Based on these data,
the size of the substituent needs to be larger than a –F group or a –OH group to bind well
to the 5-HT3 receptors. Overall, the 3-sustituted analogs analyzed earlier also follow this
trend (Table 8).
Very recent mutagenesis studies have suggested that E129 is involved in the
hydrogen-bond with the –OH in 5-HT.149 In the models created here E129 does not face
into the binding pocket. This does not mean that the model is incorrect; however, it is just
a model. Mutagenesis of E129 to A, D, G, H, N, K, or Q either decreased the pEC50 value
or there was no response. This may have also been because the mutations are not
allowing the receptor binding pocket to form correctly. The model generated using
Modeller (i.e., Method B) is a more reliable model than the model generated using Sybyl
(i.e., Method A) because it has allowed for flexibility in not only building the receptor
model but also in the docking algorithms. The rigidity of the model generated using
Sybyl (i.e., Method A) does not allow the ligands to dock to the receptor as closely as
those proposed in the literature.
6. Designed Ligand

The ligand designed on the basis of the Method A modeling studies (e.g., see
Figure 22), N-(3-chloro-4-hydroxyphenyl)guanidine (51) (Figure 24), was synthesized by
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the method outlined in Scheme 2. The target compound is a known compound.150 The
nitro intermediate (53) was obtained by sonnication of 2-chlorophenol (52) with nitric
acid (9% aqueous).151 The nitro group was then reduced using sodium hydrosulfite and
aqueous sodium hydroxide.152 An ethanolic solution of the HCl salt of aniline 54 was
heated at reflux with cyanamide (50% aqueous) to give 51.150 The structure was
confirmed by IR, 1H NMR, and melting point.
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Reagents and conditions: a. HNO3, 1,2-dichloroethane, sonnication; b. Na2S2O4, NaOH,
H2O, reflux; c. HCl, EtOAc; d. NH2CN, EtOH, reflux.

B. Conformationally-Constrained Analogs
1. Synthesis of 2-Amino-7-chloro-3,4-dihydroquinazoline (46)

The synthesis of 2-amino-7-chloro-3,4-dihydroquinazoline (46) was performed as
described in Scheme 3. This was a novel compound at the time of its synthesis, and its
method of preparation followed a literature procedure for the synthesis of 2-(alkylamino)5,6- and 6,7-dihydroxy-3,4-dihydroquinazolines.153 S-Methylisothiourea sulfate, sodium
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carbonate, and 4-chloroisotoic anhydride (55) were heated at reflux in 80% aqueous
acetonitrile. After cooling the reaction mixture to room temperature, 2-amino-7chloroquinazolin-4-(3H)-one (56) precipitated from the solution and was collected by
filtration. This intermediate (i.e., 56) was reduced using borane in tetrahydrofuran and the
HCl salt 46 was prepared. The structural assignment is consistent with IR, 1H NMR, and
elemental analysis.
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Reagents and conditions: a. S-methylisothiourea sulfate, Na2CO3, CH3CN (80%),
reflux; b. BH3-THF, reflux, c. HCl

2. Synthesis of 2-Amino-6-chloro-3,4-dihydroquinazoline (47)

2-Amino-6-chloro-3,4-dihydroquinazoline (47) was re-synthesized for this study
by the route outlined in Scheme 3 except that 5-chloroisotoic anhydride (57) was used in
place of 4-chloroisotoic anhydride (55). It was found that the product yield was much
higher (84% versus 19%) and the reaction time much shorter (6 h versus 20 h) using
aqueous acetonitrile (80%) rather than 1,4-dioxane, which was used previously for the
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synthesis of 2-amino-6-chloroquinazolin-4-(3H)-one (58).132 The physicochemical and
spectral character of 47 was consistent with an authentic sample prepared earlier in this
laboratory.132 A comparison of 46 and 47 on TLC showed little differences in Rf values
regardless of eluant system (i.e., H2O, CH3OH, CH2Cl2:CH3OH:NH4OH 9:1:0.1).
3. Binding Studies

The new quinazoline analog 46 was evaluated, and the quinazoline analog 47 was
re-evaluated for binding at the mouse 5-HT3A receptor. Compound 47 was found to bind
with the highest affinity out of the three quinazoline analogs (Table 12). This is
interesting since it would be the equivalent of 4-chlorophenylguanidine (29; Ki = 320
nM) and thus indicating that neither meta-position is important for binding at the 5-HT3
Table 12. Binding affinity of quinazoline series at 5-HT3 receptors.

-Cl
Compound position
5
48
6
47
7
46
a

Ki nMa
NG108-15
GR65630
34

Ki nMb
HEK293
Granisetron
1148
123

Ki nM (SEM)c
NIH3T3
LY 278,584
1325 (257)
80 (11)
1975 (168)

NG108-15 mouse/rat recombinant receptors express 5-HT3A; Previously
reported by Rahman et al.9
b
HEK293 human native receptors express 5-HT3AB; Dr. M. White (personal
communication).
c
NIH3T3 mouse recombinant receptors express 5-HT3A; Ki values were
generously provided by the National Institute of Mental Health's Psychoactive
Drug Screening Program, Contract # NO1MH32004 (NIMH PDSP)154
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receptor. But, since it has been shown that one of the meta-positions is important for the
binding of arylguanidines (see previous section on halogen analogs), these constrained
analogs might not bind in the same manner as MD-354 (2). The three sets of binding data
presented in Table 12 were obtained from three different laboratories. The discrepancies
in the binding data may be contributed to the different types of cells used (i.e., NG10515, HEK293, NIH3T3) and thus variations in the population type of 5-HT3 receptors (i.e.,
homomeric mouse 5-HT3A or heteromeric human 5-HT3AB). Or it may be the result of
the radioligand used (i.e., GR65630, granisetron, and LY 278,584).
Analogs 47 and 48 were submitted for functional assay and were identified as
antagonists for 5-HT3 receptors using whole cell patch-clamp experiments. MD-354 (2),
47, and 48 were investigated using this functional assay. MD-354 was found to be an

agonist in this assay with an EC50 value of 3.24 (± 0.55) μM. Quinazolines 47 and 48
were found to be antagonists with IC50 values of 4.39 (± 0.78) and 16.53 (± 5.18) μM,
respectively (Dr. M. Schulte, personal communication, unpublished data). This functional
data indicates that this quinazoline series is a novel class of 5-HT3 receptor antagonists.
4. Log P Analysis

An analysis of the log P values for the quinazoline series of compounds was
conducted in the same manner as with the arylguanidine series (Figure 29). Because these
are positional isomers, it might be expected that their log P values would be very similar.
The predicted log P value for each is 1.79 (Table 13). Constraining the guanidine by
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introducing a methylene bridge between the terminal amine and the aromatic ring makes
the compound more lipophilic than MD-354 (2; predicted log P = 1.43; Table 11) so that
it should more readily cross the BBB. The actual log P values as determined using HPLC
for the three quinazolines are nearly identical; 46 had a log P value of 1.933, 47 has a log
P value of 1.859, and 48 had a log P value of 1.889 (Table 13).
Table 13. Capacity factors ( log kw' ) determined by linear regression and calculated/

determined log P values for the quinazolines.
Compound
48
47
46
a

Position
of Cl
5
6
7

log kw'
0.4388 ± 0.01562
0.4175 ± 0.00654
0.4712 ± 0.03175

Predicted
log Pa
1.79
1.79
1.79

log P
(HPLC)
1.89
1.86
1.93

Predicted using ChemDraw.

0.42

7-Cl (46)
6-Cl (47)
5-Cl (48)

log k'

0.40
0.38
0.36
0.34
0.32
50

60

70

80

% acetonitrile

Figure 29. Linear regression analysis from the logk ' values of 46, 47, 48 at various
concentrations of acetonitrile for the quinzaoline analogs.
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The log P values determined for the quinazoline analogs (i.e., approximately 1.9)
fall within the range of log P values that are expected to cross the BBB (i.e., 1.5-2.5).
Since they should be able to cross the BBB they should be able to act at centrally-located
5-HT3 receptors.
5. Behavioral Studies
a. Tail Suspension Test

The partial agonist MD-354 (2) and quinazoline analogs 46-48 were tested for
antidepressant activity using the mouse tail suspension assay (n = 8-11 mice/dose).
Tricyclic antidepressants (i.e., desipramine and imipramine; 20 mg/kg), an SSRI (i.e.,
fluoxetine; 20 mg/kg), and a 5-HT3 receptor antagonist (i.e., ondansetron; 0.1 µg/kg)
were given by ip injection thirty minutes before the test and were used as controls. The
doses of the controls (i.e., TCAs, SSRI, and ondansetron) and the length of the test were
chosen based on literature studies.15,155 The tests were video recorded and the immobility
times for each mouse were measured in triplicate. A one-way analysis of variance
(ANOVA) showed that all of the standards displayed statistically lower immobility times
when compared with saline (Figure 30). The strain of mice used in this study was the ICR
strain; this strain has not typically been used in literature studies since ICR mice tend to
be more active than other strains. In fact, van der Hayden et al.156 and Nomura et al.157
have shown imipramine to be inactive in ICR mice (i.e., 3, 10, 30 mg/kg and 10 mg/kg,

74
respectively). Both studies used automated devices to determine immobility rather than
manual observation that was used in the present study.

Immobility time (s)

90

60

*

30

*

*

*

Sa
lin
e

Im
ip
ra
m
in
e
D
es 20
ip
ra
m
in
e
2
Fl 0
uo
xe
tin
e
O
nd 20
an
se
0. tro
00 n
01

0

Drug Dose (mg/kg)

Figure 30. Effect (± SEM) of standards (ip) on duration of immbolity in the mouse tail
suspension test (n = 8-11 mice/treatment). The significance of the effect was evaluated
with a one-way ANOVA test (F4,41 = 3.256, p < 0.05), Newman-Keuls post-hoc test (p <
0.05).

The quinazoline analogs (i.e., 46 and 47) as HCl salts and MD-354 as a nitrate
salt, were injected ip thirty minutes before the test at doses ranging from 0.1 to 30 mg/kg.
The quinazoline analog (i.e., 48) as HBr salt was injected ip thirty minutes before the test
at doses ranging from 0.1 to 10 mg/kg. The 6-Cl and 7-Cl analogs (i.e., 47 and 46,
respectively) exhibited statistically lowered immobility times when compared to saline
(Figure 31). Using a one-way ANOVA the 6-Cl analog (i.e., 47; Ki = 80 nM) exhibited
statistically significant lowered immobility times at the 1.0 and 3.0 mg/kg doses (F6,58 =
3.232, p < 0.01; Dunnett’s post-hoc test p < 0.01, p < 0.05, respectively). Using a one-
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way ANOVA the 7-Cl analog (i.e., 46; Ki = 1975 nM) exhibited statistically significant
lowered immobility times at the 0.1, 0.3, and 1.0 mg/kg doses (F6,63 = 5.036, p < 0.01;
Dunnett’s post-hoc test p < 0.05, 0.1 and 0.3 mg/kg doses; p < 0.01, 1.0 mg/kg dose). The
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Figure 31. Effect (± SEM) of 46 (top left), 47 (top right), 48 (bottom left), and 2 (bottom
right) (ip) on duration of immobility in the mouse tail suspension test (n = 8-10
mice/treatment). The significance of the effects were evaluated using one-way ANOVA
tests. For 46 (F6,63 = 5.036, p < 0.01), Dunnett’s post-hoc test (** p < 0.01, * p < 0.05).
For 47 (F6,58 = 3.232, p < 0.01), Dunnett’s post-hoc test (** p < 0.01, * p < 0.05).
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5-Cl analog (i.e., 48; Ki = 1148 nM) did not exhibit significantly lowered immobility time
for any of the doses examined (Figure 31). MD-354 (2; Ki = 166 nM) exhibited reduced
immobility times which were not significantly different than saline (Figure 31). MD-354
and 48 produce a saline-like effect in the mouse tail suspension test. The log P values
determined for all four of these compounds suggest that they can easily cross the BBB.
The decreased immobility time is the result of these compounds acting at a central
receptor. Since these compounds were given by ip injection (i.e., injection into the body
cavity) and some doses display a significant effect it can be assumed that they are
crossing the BBB and acting at a centrally located receptor as the log P data suggested
from the HPLC analysis.
As shown in Figure 31, 6-chloroquinazoline 47 seems to behave as antidepressant
at 1.0 and 3.0 mg/kg doses. But the immobility time, while still reduced, is higher at
doses greater than 3.0 mg/kg and less than 1.0 mg/kg resulting in a U-shaped doseresponse curve. This curve can also been seen with the 7-chloroquinazoline analog (46)
and MD-354 (2) but it is not as pronounced. The U-shape dose-response curve is
characteristic for 5-HT3 receptor ligands in biological assays.5 With regards to agonists,
this type of dose-response curve can be explained by desensitization of the receptor.
However, with regards to antagonists the underlying mechanism has yet to be explained.
One possible explanation is that 5-HT3 receptor antagonists may bind differently at the
homomeric 5-HT3A receptors and heteromeric 5-HT3AB receptors.5,158
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The 7-Cl analog (46) does not bind with high affinity (Ki = 1975 nM) to 5-HT3
receptors but displays lower immobility scores than saline; this may indicate that it acts
via a non-5-HT3 receptor mechanism to produce this effect. During the course of this
investigation Peters et al.159,160 reported the synthesis of a number of cyclic guanidines,
including 46-48, through high throughput screening methods. They showed that some
bind both to 5-ht5a and 5-HT7 receptors (Table 14). Peters et al. report prompted us to test
our analogs for binding affinity at 5-ht5a and 5-HT7 receptors. We have found that the 7Cl analog binds at 5-ht5a and the 5-HT7 receptors (Ki = 302 and 310 nM, respectively)154
with 5-fold higher affinity than at 5-HT3 receptors. Interestingly, the 5-HT7 receptor has

Table 14. Binding profile of selected cyclic guanidines at 5-HT3, 5-ht5a, and 5-HT7
receptors.

Compound
48
47
46

R
5-Cl
6-Cl
7-Cl

5-HT3
1325 ± 257 1051b
80 ± 11a
—
a
1975 ± 168
—

a

5-ht5a

155
357 ± 38a
302 ± 48a

b

99
807b
347b

a

5-HT7

1109
1701 ± 242a
310 ± 43a

793b
—
—

a

Ki values were generously provided by the National Institute of Mental Health's Psychoactive Drug
Screening Program, Contract # NO1MH32004 (NIMH PDSP)154
b
Peters et al.159

been implicated in depression.161 A recent review by Mnie-Filali et al. showed that 5-HT7
receptor KO mice display antidepressant-like behavior in the FST and TST relative to
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WT mice.161 In addition, the administration of the 5-HT7 receptor antagonist SB-269970
also decreased immobility time.161 Therefore, the 5-HT7 receptor mechanism in the
antidepressant action of 46 cannot be excluded. The 5-ht5a receptor’s function is not fully
understood because of the lack of selective agents. However, since it is located only in
the CNS, primarily in the cerebral cortex, hippocampus, and cerebellum, it has been
postulated that this receptor may be involved in schizophrenia or mood disorders.162,163
Based on this information 47 could be exhibiting its antidepressant effect through a 5-ht5a
or 5-HT7 receptor mechanism. Interestingly, the 5-chloroquinazoline 48 seems to be more
selective for the 5-ht5a receptor over the 5-HT3 and 5-HT7 receptors. Optimization of this
analog by Peters et al. has led to even more analogs that have increased binding affinity
for 5-ht5a receptors (e.g., 2-amino-5-chloro-4-methyl-3,4-dihydroquinazoline; 5-ht5a Ki =
5.1 nM).159,160 The 5-Cl-4-CH3 analog was also shown to be a competitive 5-ht5a receptor
antagonist through the [35S]GTPγS assay with a pA2 value of 8.52.159 Most of their
analogs had no more than a 4-fold selectivity over the 5-HT7 receptors but because of the
similar localization of the 5-ht5a and 5-HT7 receptors in the brain, Peters et al. continued
to examine this series.159 Their overall goal was to develop a pharmacological tool for
behavioral studies to examine the role of the 5-ht5a receptor’s antipsychotic-like
effects.160 Although the involvement of a 5-HT7 receptor mechanism in the antidepressant
activity of 46 cannot be excluded at this time, it is unlikely to undermine the
antidepressant activity of these quinazoline analogs because 47 binds with more than 20fold lower affinity at 5-HT7 receptors versus 5-HT3 receptors.
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b. Locomotor Activity Assay

Since hypermobility may also explain lowered immobility times relative to saline,
the effective tail suspension test doses (46, 0.3 mg/kg; 47, 1.0 and 3.0 mg/kg) were tested
against saline for hyperactivity using the locomotor activity assay. The doses were
injected ip with no pre-treatment time and their effect on locomotor activity was
examined over 45 minutes. This time encompasses the 30 minutes pretreatment from the
tail suspension test, the six minute tail suspension test, and nine minutes after the tail
suspension test would be over; so any movements that have increased relative to saline
during this time would have been increased during the antidepressant assay.
Using a one-way ANOVA there was no significant difference between any of the
doses and saline for the 45 minute duration for total movement episodes, total movement
time, total movement distance, number of jumps or average velocity (Figure 32). These
parameters are usually used in the identification of stimulants. Stimulants generally
increase the movement time, distance, and velocity but decrease the number of movement
episodes (i.e., the drug increases the duration of motor activity but decreases the number
of stops).164 There was also no difference from saline for the retraced local movements,
retraced local movement episodes (3 repeated local movements), and these movements’

80
2000

Movement time (s)

Movement episodes

500
400

1500

300

1000

200
100
0

1.0
Saline

3.0

6-Cl (47)

500
0

0.3
7-Cl (46)

1.0
Saline

Drug Dose mg/kg

6-Cl (47)

0.3
7-Cl (46)

Drug Dose mg/kg
80

6000

60

Jumps

8000

Movement distance (cm)

3.0

4000
2000

40
20

0

1.0
Saline

3.0

6-Cl (47)

0

0.3
7-Cl (46)

1.0
Saline

Drug Dose mg/kg

3.0

6-Cl (47)

0.3
7-Cl (46)

Drug Dose mg/kg

Velocity (cm/s)

4
3
2
1
0

1.0
Saline

3.0

6-Cl (47)

0.3
7-Cl (46)

Drug Dose mg/kg

Figure 32. Effect (± SEM) of 47 (1.0 and 3.0 mg/kg) and 46 (0.3 mg/kg) on total number
of movement episodes, total movement time, total movement distance, total number of
jumps, and average velocity (n = 12-13 mice/treatment).
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time which may indicate exploratory behavior (Figure 33). The term local refers to the
fact that the animal’s movement does not produce a large enough change in location from
its starting point (i.e., less than ±1.499 beam spaces from the starting point). As with all
of the other parameters examined there was no difference using a one-way ANOVA
between the doses evaluated and saline for margin distance traveled, time spent in the
margin, center distance traveled, time spent in the center, number of center entries, and
the number of vertical entries (Figure 34). Increased margin activity or decreased central
activity is generally viewed as an anxiogenic-like effect. Vertical entries may indicate the
“nonspecific excitability level” of the animal.
The 5-HT3 receptor antagonist ondansetron (3) and the 5-HT3 receptor partial
agonist MD-354 (2) showed no effect on locomotor activity in previous studies.15,132
Based on those results, there was no reason to expect a change in locomotor activity for
the quinazoline analogs 46 and 47 unless these compounds cause hyperactivity. Since
there was no difference in activity from saline using a one-way ANOVA with any of the
doses examined, the lowered immobility scores from the tail suspension test should be
from an antidepressant-like action of the compounds and not from hyperactivity.
However, 46 displayed a decreased number of center entries, a decreased amount of time
spent in the center of the arena, and a decreased distance traveled in the center of the
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Figure 33. Effect (± SEM) of 47 (1.0 and 3.0 mg/kg) and 46 (0.3 mg/kg) on total number
of retraced local movements, total number of retraced local movement episodes, and total
time spent on retraced local movements (n = 12-13 mice/treatment).

arena, but they were not found to be significantly different from saline using a one-way
ANOVA. A significant decrease in center activities may have indicated anxiogenic-like
properties. Because these parameters were not significantly different than saline using a
one-way ANOVA, this may be because of variation and not a true example of anxiogenic
properties. If it is because of anxiogenic properties, it is most likely the result of acute
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administration; there have been reports indicating that some antidepressants increase
anxiety levels when administered acutely.165,166
6. Molecular Modeling

Since the constrained analogs 47 and 48 were found to be antagonists for the 5HT3 receptor, it would be of value to identify the docking poses of these constrained
analogs to a 5-HT3 receptor homology model. Using the same set of models generated
using Modeller (Method B) and AutoDock4, the 5-HT3 receptor anatagonist granisetron
(4), with the charges and geometries generated by MOPAC, was docked to each of the
five interfaces of each of the 100 models with 20 genetic algorithms in a 40 Å x 40 Å x
40 Å region around the C-loop. A different model than the model identified by the
agonist 5-HT, was identified through the proposed binding mode of the antagonist
granisetron. This proposed binding mode is similar to that in the literature for granisetron
(Figure 35).167,168 The azabicyclic ring is located towards W90 and F226, while the
aromatic ring is located towards W183 and Y234. ProCheck was used to create a
Ramachadran plot of the pentamer; it was found that 64.8% of residues were in favored
regions, 28% in additionally allowed regions, 4.8% in generously allowed regions and
2.5% in disallowed regions (Figure 36). Since the loop models are generated by small
changes in energies, the side chains were not optimized with SCRWL leading to residues
found in the generously allowed and disallowed regions as seen with the 5-HT3 receptor
agonist model also developed by Modeller. In addition, AutoDock allowed for flexibility
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in the backbone atoms during the docking process to allow for the best possible
interactions.

Figure 35. Proposed binding mode of granisetron (4) to the h5-HT3A receptor antagonist
model developed using Modeller (Method B). Granisetron is shown in magenta and
residues within 5 Å are shown.

Since this antagonist model could be validated by granisetron (4), the quinazoline
analogs 46-48 and the 5-HT3 receptor partial agonist MD-354 (2) were built and given
geometries and charges according to MOPAC. They were docked to the antagonist
validated receptor model using AutoDock and the same parameters as before. The
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guanidine portion of the quinazolines is oriented towards W90 instead of towards W183
as seen with the MD-354 (Figure 37). An overlap of MD-354 (2) and the highest binding
affinity analog, 6-Cl quinazoline 47, is shown in Figure 38.

Figure 36. Ramachadran plot of the h5-HT3A receptor antagonist model developed using
Modeller (Method B).
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Figure 37. Proposed binding mode of the quinazoline analogs 46-48 to the h5-HT3A
receptor anatagonist model developed using Modeller (Method B). The 5-Cl analog (48)
is shown in cyan, the 7-Cl analog (46) is shown in yellow, and the 6-Cl analog (47) is
shown in purple. Residues within 5 Å are also shown.

Based on the structures of the quinazolines and MD-354, it was assumed that the
quinazolines should be able to bind overlapping MD-354. However, based on the
proposed binding modes, the quinazoline analogs do not bind in the same manner as the
partial agonist MD-354. But bind in the opposite direction as MD-354 (Figure 38). The

88

Figure 38. Overlap of the proposed binding modes of MD-354 (2; cyan) and the highest
binding affinity analog, 6-Cl quinazoline 47 (purple).

guanidine of the quinazolines may be interacting with W90 instead of W183 as seen with
the proposed binding mode of MD-354. These changes in proposed binding modes may
explain why the quinazolines are antagonists and MD-354 is merely a partial agonist. The
constrained guanidine cannot make the same interactions (W183 and Y234) with its
nitrogen atoms as the free guanidine of MD-354. This may also explain why neither of
the two rotameric constrained analogs of MD-354 (i.e., 46 and 48) bind with the same
affinity as MD-354.
7. Synthesis of 2-Amino-8-chloro-1,3-benzodiazepine (49)

The synthesis of this constrained analog of MD-354 (2) would allow for a longer
centroid-to-amine distance, closer to that of MD-354, and a larger height of the primary
amine above the plane of the aromatic ring (Table 6). The first attempted synthesis
followed the reaction outlined in Scheme 4. The benzoic acid 59 was reduced to the
benzyl alcohol 60.169 An attempt was made to convert the benzyl alcohol to the benzyl
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bromide 61.170 However, the benzyl bromide was unable to be isolated and characterized
with and without first protecting the amine (i.e., (Boc)2O or trifluoroacetic anhydride).
Scheme 4.a

59

49

60

63

61

62

R = H, Boc, TFA
a

Reagents and conditions: a. LiAlH4, THF (R = H); b. PBr3, CH2Cl2 or Et2O; c. NaCN,
isopropanol, H2O, d. Raney Ni, e. BrCN, EtOH

The second route of synthesis involved the opening of the oxindole ring 64 to
obtain the carboxylic acid 65.171 Under the conditions described in Scheme 5 the desired
ring-opened intermediate was not isolated. Either it was formed, and then recyclized to
the starting material (i.e., 64), as the use of acid is typically employed to prepare
oxindoles from the 2-aminophenylacetic acids,172 or only tautomer 66 of the starting
material was formed which then reverts back to starting material. The NMR and IR
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analysis of the product from the reaction could not conclusively be identified as either 65
or 66 but was different from 64 on TLC.
Scheme 5.a

64

66

65

67

49

63

a

Reagents and conditions: a. NaOH, H2O, reflux; b. HCl, H2O; c. carbonyldiimidazole,
NH3, CH3OH, d. BH3-THF, e. BrCN, EtOH

The third route of synthesis involved the conversion of nitrotoluene 68 to
benzaldehyde 69 with DMF-DMA,173 then converting the benzaldehyde to a nitrostyrene
70 with nitromethane174 as outlined in Scheme 6. The benzaldehyde 69 could not be

purified from bi-products formed during the reaction.
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Scheme 6.a

68

69

49

70

63

a

Reagents and conditions: a. 1. DMF-DMA, 140 °C, 2. NaIO4; b. CH3NO2, NH4OAc,
reflux, c. SnCl2, HCl, d. BrCN, EtOH

The fourth route of synthesis attempted to convert benzoic acid 71 to
nitrophenylethanone 73 going through intermediate 72 as outlined in Scheme 7.175
However, only the intermediate 72 was formed and isolated; the nitrophenylethanone 73
was not. It appears that the intermediate does not react as easily with the nitromethane as
suggested in the literature.
The fifth route of synthesis involved the reaction of nitrotoluene 68 with Nbromosuccinamide and benzoyl peroxide to form benzyl bromide 75 (Scheme 8).176 The
benzyl bromide was slightly more polar than the starting material and has a very similar
melting point making separation difficult. An attempt to convert benzyl bromide 75 to
(nitrophenyl)acetonitrile 76 using hydrogen cyanide formed in situ from sodium cyanide

92
Scheme 7.a

71

49

72

73

63

74

a

Reagents and conditions: a. carbonyldiimidazole, K2CO3, THF, CH3NO2, reflux; b. BH3THF; c. SnCl2, HCl; d. BrCN, EtOH

and strong acid resulted in the formation of a dimer complex (i.e., 77). This type of
dimerization was seen by Kalir and Mualem with the reaction of 2-nitrobenzylbromide
using this reaction.177 Another attempt to convert the benzyl bromide 75 to
(nitrophenyl)acetonitrile 76 was made using liquid-liquid phase transfer catalysis.
Sodium cyanide ionizes in water into a sodium ion and cyanide ion. The cyanide reacts
with 75 to form 76, and then quickly reacts with another equivalent of 75 to form 2,3bis(4-chloro-2-nitrophenyl)propanenitrile (77). Adjusting the pH to be acidic to increase
the ionization of the cyanide completely halted the reaction. Using solid-liquid phase
transfer catalysis with potassium cyanide, 18-crown-6 ether, in acetonitrile still produced
77 and not 76 as desired.
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Scheme 8.a

68

77

75

49

76

63

Reagents and conditions: a. N-bromosuccinamide, benzoyl peroxide, CCl4, light, reflux;
b. NaCN, H2O, TBAB, CH2Cl2; c. BH3-(CH3)2S, reflux; d. Raney Ni; e. BrCN, EtOH,
reflux
Given that the height of the amine above the plane and the aromatic centroid to
primary amine distances of 49 are closer to that of MD-354 (2) relative to the other
constrained analogs (i.e., 45-48), 49 may bind with enhanced affinity. Since the synthesis
of 49 was unsuccessful, binding data is not available. If 49 binds with higher affinity than
46, the longer amine to centroid distance and/or the out-of-plane character of 49 might

explain the difference in binding affinities.

V. Conclusions

Two novel series of MD-354 (2) analogs were synthesized as part of this
investigation. The intended purpose of evaluating these series was to identify what
characteristics of the meta-position are necessary for binding to the 5-HT3 receptor and
which meta-position is important for binding.
The first series of analogs developed was the mono-substituted halogen analogs of
MD-354. By purely examining the binding affinity of PG (27), 3-FPG (42), MD-354 (2),
3-BrPG (43), and 3-IPG (44) it appears that smaller substituents do not bind very well at
the 5-HT3 receptors. The receptor may need a substituent at the 3-position of a particular
size or larger to have high affinity; the –H or –F groups may be too small to fit this
requirement. However, the 3-CF3 analog binds with even lower affinity than PG or 3FPG and is much larger in terms of solvent accessible volume than any of the
halogenated analogs, suggesting that something more than just size plays a role in
binding affinity. A Hansch analysis indicated that size in the form of volume (i.e., surface
accessible volume and CMR), polarizability (i.e., CMR and polarizability) and electronic
character (i.e., π) are important components in binding affinity. However, volume and
polarizability are intercorrelated and can therefore act as surrogates for each other. But a
multiple linear regression analysis has shown that π and either CMR, volume, or
polarizability impact binding affinity. All of this information is consistent with a prior
94
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QSAR analysis100,124 of arylguanidines and supports the current pharmacophore for
arylguanidines and arylbiguanides83 that at one of the meta-positions an electronwithdrawing group of a certain volume or polarizability is needed for optimal binding
affinity.
Two distinct homology models of the h5-HT3A receptor were developed by
different methods (i.e., Method A and Method B) and validated by docking the 5-HT3
receptor agonist serotonin. Upon validation of the models, the docking of the halogenated
analogs to a homology model (Method B) of the h5-HT3A receptor was investigated. The
results suggested that these analogs bind in the same manner as MD-354. However, 3FPG (42) is suggested to dock in an orientation in which the fluorine atom does not
overlap with the other halogens but is on the opposite side of the aromatic ring. This can
be explained by the effects of a fluorine atom attached to an aromatic ring. The
electronegativity of the fluorine atom might affect the electronic character of not only the
ring but also of the guanidine.
Based on the proposed docking poses of MD-354 and serotonin (Method A) a
new analog was designed and synthesized, (3-chloro-4-hydroxyphenyl)guanidine (51).
The guanidine portion should be able to interact with W183 and Y234 as the aliphatic
amine in serotonin does and the hydroxyl group should be able to interact with Y153. The
–Cl group from this compound should be able to sit in the same pocket as the –Cl group
from MD-354. In theory 51 should bind with higher affinity than 5-HT or MD-354
because it should be able to interact with the receptor similar to both 5-HT and MD-354.
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The second series of analogs developed were constrained analogs of MD-354 (2);
in which the guanidine was constrained by a methylene group to form a series of
quinazolines (i.e., 46-48). This series was initially developed to determine which metaposition was important for binding affinity. However, binding data at the 5-HT3 receptor
of these three analogs indicated that neither position was important. Since it has been
shown previously that there is an electronic effect for a meta-substituent (vide supra), at
least one meta-position is important and necessary for binding to the 5-HT3 receptor if the
compounds are binding in the same manner. Based on this data, the quinazoline series
does not seem to be binding to the 5-HT3 receptor in the same manner as the
arylguanidines. A functional assay has also shown that some of these quinazolines are
antagonists for the 5-HT3 receptor (47; IC50 = 4.39 ± 0.78 μM and 48; IC50 = 16.53 ± 5.18
μM; Dr. M. Schulte, personal communication, unpublished data).
Molecular modeling of the possible binding modes of the quinazolines to a
homology model (Method B) of the h5-HT3A receptor validated by the docking of the 5HT3 receptor antagonist granisetron, indicates that the quinazolines do not bind in the
same manner as MD-354. The quinazolines seem to bind upside-down relative to MD354 in which their guanidine portion interacts with W90 and not W183. Since this series
has been shown to be functionally different than MD-354 and does not seem to bind in
the same manner, it should be considered a novel class of 5-HT3 receptor ligands.
Some of the newly synthesized analogs (e.g., 43, 44, and 47) have higher binding
affinity for the 5-HT3 receptors than MD-354. But, having higher binding affinity had no
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effect on the ability of the compound to cross the BBB. The evidence for mCPBG (17) to
penetrate the BBB has been controversial. A newer method of determining partition
coefficients was employed using HPLC. With this method, mCPBG was shown to have a
log P value consistent with its being able to cross the BBB. The log P values determined
for PG (27), 3-FPG (42), MD-354 (2), 3-BrPG (43), 3-IPG (44), 3,4,5-tri-Cl-PG (35), 5Cl quinazoline 48, 6-Cl quinazoline 47, and 7-Cl quinazoline 46 also indicate that they
should be able to readily cross the BBB.
Considering the log P values of the quinazoline series indicates that these
compounds should be able to readily cross the BBB and interact with central 5-HT3
receptors and, considering that this is a novel series of 5-HT3 receptor ligands, their
ability to treat depression was evaluated with the mouse tail suspension test. Results from
the study indicated that some of the doses of two of the quinazolines (1.0 and 3.0 mg/kg
of 47 and 0.1, 0.3, and 1.0 mg/kg of 46) decrease immobility time relative to saline.
Whereas, the other quinazoline analog (i.e., 48) and MD-354 (2) did not statistically
decrease immobility time. Furthermore, the lowered immobility scores are not because of
increased movements of the mice as shown by saline-like effects on the locomotor
parameters assessed. However, the lack of selectivity for the 5-HT3 receptor may indicate
that the antidepressive action seen may or may not be because of a 5-HT3 receptor
mechanism. If the antidepressive action that is observed is not because of a 5-HT3
receptor mechanism, then these compounds being antagonists is not relevant. But, if the
antidepressive action that is observed is because of a 5-HT3 receptor mechanism, then

98
these compounds are behaving similarly to the other 5-HT3 receptor antagonists,
ondansetron and bemesetron; if that is the case, the 5-HT3 receptor agonist SR 57227A
may be desensitizing the receptor and producing its antidepressive effect. If the
antidepressant action of the agonist SR 57227A is from desensitization it may explain
why MD-354, a partial agonist, is inactive and that the antidepressant action is because of
an antagonist effect at the 5-HT3 receptors. However, since 5-HT3 receptors have been
implicated in anxiety, the SR 57227A could be anxiogenic and the lowered immobility
scores due to tremors from anxiety.
In conclusion, two novel series of MD-354 analogs were synthesized. The first
series, halogen analogs, was used to determine that an electronic effect at a meta-position
is essential for binding. Furthermore, the poloarizability or the volume of the substituent
is important as well for the binding of arylguanidines and arylbiguanides. It is most likely
a combination of both the electronic effect and the polarizability, or the electronic effect
and the volume, that affect binding together rather than just one individually. While the
second series, quinazoline analogs, was developed to determine which meta-position was
important, it has instead been shown to be a novel class of 5-HT3 receptor ligands. Two
of the analogs (i.e., 46 and 47) have been shown to behave as antidepressants in the
mouse tail suspension test. They may or may not be acting through a 5-HT3 receptor
mechanism since 46 binds with higher affinity to the 5-ht5 and 5-HT7 receptors and 47
only has a 4-fold selectivity over the 5-ht5 receptor. Overall the current pharmacophore
for arylguanidines and arylbiguanides has been validated for unconstrained
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arylguanidines. And a novel class of 5-HT3 receptor ligands, which are conformationallyconstrained arylguanidines, has been developed which do not fit the pharmacophore for
arylguanidines and arylbiguanides.

VI. Experimental
A. Synthesis

Melting points were taken on one of two melting point apparatuses in glass
capillary tubes and are uncorrected. Unless otherwise noted melting points were taken on
a Thomas-Hoover melting point apparatus. When noted, the melting points were taken
on a Büchi B-545 melting point apparatus. 1H NMR spectra were recorded with a Varian
EM-390 spectrometer with tetramethylsilane (TMS) as an internal standard. Peak
positions are given in parts per million (δ). Infrared spectra were obtained on a Nicolet
Avatar 360 FT-IR spectrophotometer. Microanalyses were performed by Atlantic
Microlab Inc. (Norcross, GA) for the indicated elements and results are within 0.4% of
calculated values. Chromatographic separations were performed on silica gel columns
(Silica Gel 62, 60-200 mesh, Sigma-Aldrich). Flash chromatography was performed on a
CombiFlash Companion/TS (Teledyne Isco Inc. Lincoln, NE). Reactions were monitored
by thin-layer chromatography (TLC) on silica gel GHLF plates (250 µ, 2.5 X 10 cm;
Analtech Inc. Neward, DE).
N-(3-Fluorophenyl)guanidine Nitrate (42). Compound 42 was prepared according to a

literature procedure.143 A solution of 3-fluoroaniline hydrochloride (50) (1.00 g, 6.78
mmol) and cyanamide (0.38 g, 9.04 mmol) in abs EtOH (5 mL) was heated at reflux for 6
100
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h. The solvent was removed under reduced pressure to give a pale yellow oil. The crude
product was dissolved in H2O (2 mL) and NH4NO3 (1.00 g, 12.5 mmol) was added in
excess. The solvent was removed under reduced pressure and the residue was crystallized
from H2O. The light brown crystals were collected by filtration and washed with cold
Et2O (3 x 5 mL) to yield 0.81 g (55%) of 42: mp 145-146 °C (H2O), 146-147 °C (EtOH)
(lit178 165 °C, EtOH); IR (KBr, cm-1): 3342, 3330, 3195, 1669, 1597, 1493, 1369, 1143;
1

H NMR (DMSO-d6) δ 7.21-7.04 (m, 3H, ArH), 7.53-7.45 (m, 5H, ArH, NH2, ex with

D2O), 9.72 (s, 1H, NH, ex with D2O). Anal. calcd for C7H8FN3 · HNO3: C, 38.89; H,
4.20; N, 25.92 Found: C, 39.08; H, 4.15; N, 25.89.
2-Amino-7-chloro-3,4-dihyroquinazoline, Hydrochloride (46). Compound 46 was

prepared using a literature procedure for a similar compound.153 BH3-THF complex (12.2
mL, 1 M, 12.2 mmol) was added in a dropwise manner to 56 (0.60 g, 3.06 mmol) under a
N2 atmosphere. The orange mixture was heated at reflux for 2.5 h. After cooling the
reaction mixture to room temperature, a 6 N solution of HCl (3 mL) was added in a
dropwise manner releasing gas. Then a 6 N solution of NaOH (12 mL) was added in a
dropwise manner to basify the reaction mixture. The solution was concentrated under
vacuum, and hot CHCl3 (3 x 10 mL) was added. The solid at the interface was collected
and dried under reduced pressure for 4 h to give a white solid 0.15 g, (24%): mp 183-185
°C; 1H NMR (DMSO-δ6): 3.45 (br s, 1H, NH, D2O ex), 4.30 (s, 2H, CH2), 6.12 (br s, 1H,
NH, D2O ex), 6.60 (s, 1H, ArH), 6.73 (d, 1H, ArH), 6.89 (d, 1H, ArH). A solution of the
crude product (0.13g, 0.72 mmol) in abs EtOH was cooled in an ice/water bath.
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Concentrated HCl was added in a dropwise manner to a pH  3. The solvent was
removed under reduced pressure and the process repeated twice more to give a white
solid. The solid was recrystallized from hot EtOH to give a white solid 0.08 g (53%) of
46: mp 249-251°C; IR (KBr, cm-1): 3300, 3190, 2979, 2927, 2855, 1700, 1618, 1493,

1091; 1H NMR (DMSO- δ6): 4.45 (s, 2H, CH2), 7.07 (d, 1H, ArH), 7.17 (dd, 1H, ArH),
7.25 (d, 1H, ArH), 7.77 (s, 2H, NH2, 1H D2O ex), 8.63 (s, 1H, NH, D2O ex), 11.02 (s,
1H, NH, D2O ex). Anal calcd for C8H8N3Cl · HCl · 0.25 H2O: C, 43.17; H, 4.30; N, 18.88
Found C, 43.37; H, 4.07; N, 18.55.
2-Amino-6-chloro-3,4-dihyroquinazoline, Hydrochloride (47). Compound 47 was

prepared according to a literature procedure for a similar compound.153 BH3-THF
complex (11.6 mL, 1 M, 11.6 mmol) was added in a dropwise manner to 58 (0.65 g, 3.33
mmol) under a N2 atmosphere. The orange mixture was heated at reflux for 2 h. After
cooling the reaction mixture to room temperature, a 6 N solution of HCl (3 mL) was
added in a dropwise manner releasing gas. Then a 6 N solution of NaOH (12 mL) was
added to basify the mixture. The solution was concentrated under vacuum, and extracted
with hot CHCl3 (20 mL x 3). The solvent was removed under reduced pressure to give a
white solid 0.28 g (46%): mp 227-230 °C (lit132 225-230 °C, EtOH). A solution of the
crude product (0.28 g, 1.51 mmol) in abs EtOH was cooled in an ice/water bath.
Concentrated HCl was added in a dropwise manner to pH  3. The solvent was removed
under reduced pressure and the process repeated twice more to give a white solid. The
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solid was recrystallized from EtOH to afford a white crystalline solid 0.26 g (80%) of 47:
mp 237-240°C (lit132 237-238 °C, EtOH).
N-(3-Chloro-4-hydroxyphenyl)guanidine, Hydrochloride (51). Compound 51 was

prepared according to a literature procedure.150 A solution of 54 (0.13 g, 0.72 mmol) and
cyanamide (0.046 g, 1.08 mmol, 50% aq solution) in abs EtOH was heated at reflux for
18 h. After allowing the purple solution to cool to room temperature, it was cooled
further to -25 °C (in the freezer). A purple precipitate formed and was collected by
filtration and washed with cold EtOH. The solid was dried under reduced pressure for 2 h
over toluene to give 51 (0.080 g, 0.36 mmol, 50%) as a purple solid: mp 239-241 °C,
251-254 °C (Büchi melting point apparatus) (lit150 244-246 °C dec, EtOH); 1H (DMSOd6): 2.53 (s, 1H, OH), 7.05 (s, 1H, ArH), 7.26-7.40 (d, 2H, ArH); IR (KBr, cm-1) 3370,
1287.
2-Chloro-4-nitrophenol (53). Compound 53 was prepared according to a literature

procedure.151 Nitric acid (10.9 mL H2O, 9% wt) was added in a dropwise manner to a
solution of 2-chlorophenol (52) (0.50 g, 3.89 mmol) in 1,2-dichloroethane (12.5 mL). The
reaction mixture was sonnicated for 3 h, then washed with H2O (3 x 25 mL) and
extracted with CH2Cl2 (3 x 25 mL). The combined organic portion was dried (Na2SO4),
and the solvent was evaporated under reduced pressure to give a yellow, oily residue.
Purification by flash chromatography on a silica gel column using hexanes/EtOAc (9:1)
as eluent gave a crude yellow solid. The product was recrystallized from petroleum ether
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to afford yellow crystals 0.24 g (35%) of 55: mp 106-108 °C (lit152 106-110 °C, H2O and
AcOH).
3-Chloro-4-hydroxyaniline, Hydrochloride (54). The free base of compound 54 was

prepared according to a literature procedure.152 Sodium hydrosulfite (1.20 g, 6.91 mmol)
was added in ten equal portions (0.12 g) over 10 min to a solution of 53 (0.30 g, 1.73
mmol) in H2O (2 mL with 0.83 g, 20.74 mmol NaOH) heated at reflux. The reaction
mixture was heated at reflux until the red color disappeared (approximately 20-30 min).
After cooling to room temperature, a precipitate formed and was filtered then washed
with cold H2O. The filtrate was extracted with Et2O (3 x 15 mL), the organic layer was
dried (Na2SO4), and the solvent was removed under reduced pressure to afford a gray
powder 0.13 g (50%) (which turned brown over time) of the free base of 54: mp 149-151
°C (lit152 150-151 °C, H2O). The free base (0.125g, 0.87 mmol) was dissolved in EtOAc,
cooled in an ice/water bath, and charged with N2 (g). HCl (g) was bubbled in for 10 min.
After 30 min of standing on ice the suspension was filtered to give 54 (0.13 g, 83%) as a
pale gray solid: mp > 250 °C.
2-Amino-7-chloro-quinazolin-4-(3H)-one (56). Compound 56 was prepared according

to a literature procedure for a similar compound.153 S-Methylisothiurea sulfate (1.4 g,
5.06 mmol) and Na2CO3 (0.58 g, 5.47 mmol) were added to a solution of 4-chloroisatoic
anhydride (55) (1.00 g, 5.06 mmol) in CH3CN (24 mL, 80%) and heated at reflux for 5 h.
The reaction mixture was allowed to cool to room temperature over 30 min and the
precipitate was collected by filtration. The solid was washed with CH3CN (80%, 3 x 25
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mL) then dried under reduced pressure over toluene for 16 h to give 56 (0.64 g, 65%) as a
pale pink solid: mp > 300 °C (lit179 > 300 °C); IR (KBr, cm-1) 3401, 2133, 1597, 1442,
1101; 1H NMR (DMSO-δ6): 6.58 (br s, 2H, NH2, D2O ex), 7.11 (dd, 1H, ArH), 7.21 (d,
1H, ArH), 7.87 (d, 1H, ArH), 11.10 (br s, 1H, NH, D2O ex).
2-Amino-6-chloro-quinazolin-4-(3H)-one (58). This compound was prepared according

to a literature procedure for a similar compound.153 5-Chloroisatoic anhydride (57) (1.00
g, 5.06 mmol) was dissolved in CH3CN (24 mL, 80%), then S-methylisothiourea sulfate
(1.4 g, 5.06 mmol) and Na2CO3 (0.58 g, 5.47 mmol) were added to the solution. The
resulting solution was heated at reflux for 6 h. The reaction was allowed to cool to room
temperature over 0.5 h. The suspension was filtered and washed with CH3CN (80%, 25
mL x 3). The solid was dried under reduced pressure for 16 h to give a pale pink solid
0.67 g (67%): mp >300 °C (lit9 >300 °C).
2-Amino-4-chlorobenzylalcohol (60, R = H). Compound 60, R = H, was prepared

according to a literature procedure.169 A suspension of LiAlH4 (0.33 g, 8.74 mmol) in
anhydrous THF (50 mL) was cooled to 0 °C in an ice/water bath under N2 atmosphere. 2Amino-4-chlorobenzoic acid (59, R = H) (1.0 g, 5.83 mmol) in THF (25 mL) was added
in a dropwise manner. The mixture was allowed to stir in an ice/water bath for 30 min,
room temperature for 30 min, then heated at reflux for 40 min. The mixture was cooled to
0 °C in an ice/water bath and an aqueous solution of THF (THF:H2O, 2:1) was added.
The precipitate was removed by filtration and washed with THF (3 x 10 mL). The filtrate
was dried (MgSO4) and the solvent was removed under reduced pressure. The resulting
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solid was purified by column chromatography (hexanes:EtOAc, 2:1; hexanes:EtOAc, 1:1;
EtOAc). The crude product was recrystallized from i-PrOH to give white crystals 0.80 g
(87%) of the title compound: mp 139-140 °C (Lit169 140-142 °C).
2-Amino-4-chlorobenzylbromide (61, R = H). Method A. Compound 61 (R = H) was

attempted to be prepared according to the literature procedure for a similar compound.180
Phosphorous tribromide (0.09 g, 0.33 mmol) was added to a suspension of 60 (R = H)
(0.10 g, 0.63 mmol) in Et2O (3 mL) while stirring in an ice/water bath. The solution was
stirred for 1 h then NH4Cl (saturated, 5 mL) was added and gas evolved. Water (5 mL)
was added, and the reaction mixture was extracted with Et2O (3 x 5 mL). The Et2O layer
was washed with brine (5 mL) and dried (MgSO4). The solvent was removed under
reduce pressure. Compound 61 (R = H) could not be isolated.
Method B. Compound 61 (R = H) was attempted to be prepared according to the

literature procedure for a similar compound.181 Phosphorous tribromide (0.34 g, 1.27
mmol) was added to a stirred solution of 60 (R = H) (0.10 g, 0.63 mmol) in CH2Cl2 (10
mL). The solution was stirred at room temperature for 4 h then quenched by the addition
of H2O (10 mL). The reaction mixture was extracted with CH2Cl2 (3 x 10 mL), washed
with brine (10 mL), and dried (MgSO4). The solvent was removed under reduced
pressure. Compound 61 could not be isolated.
2-(2-Amino-4-chlorophenyl)acetic Acid (65). Attempts were made to prepare this

compound according to a literature procedure.171 6-Chlorooxindole (0.20 g, 1.19 mmol)
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was suspended in 4 M NaOH (3 mL). The mixture was heated at reflux for 4.5 h, then
cooled to room temperature. The precipitate was removed by filtration and washed with
Et2O. The solid was dissolved in H2O (5 mL) and 6 N HCl was added in a dropwise
manner while the solution was allowed to stir in an ice bath until a precipitate formed.
The pale brown precipitate was collected: mp 195-197 °C. The filtrate was basified with
6 N NaOH and extracted with Et2O (3 x 20 mL) and dried (Na2SO4). The solvent was
removed to give a pale brown solid: mp 192-195 °C. The melting points of both solids
matched the melting point of the starting material 64: mp 195-199 °C; 1H NMR (DMSOδ6) 3.44-3.54 (t, 2H), 3.94 (br s), 6.84 (s, 1H), 6.97-7.00 (d, 1H), 7.21-7.24 (d, 1H), 10.57
(s, 1H); IR (KBr, cm-1) 3370, 1555, 1483, 1390, 1091. The literature171 melting point for
65: 251-254 °C.
4-Chloro-2-nitrobenzaldedhyde (69). Compound 69 was prepared according to a

literature procedure.173 A solution of 68 (2.5 g, 12.2 mmol) and DMF-DMA (4.36 g, 36.6
mmol) was allowed to stir in a 135 °C (oil bath) for 11 h then cooled to room
temperature. The reaction mixture was added in a dropwise manner to a solution of
NaIO4 (7.8 g, 36.5 mmol) in H2O (25 mL) and DMF (12.5 mL). After 3 h the suspension
was filtered and the precipitate washed with toluene. The layers were separated and the
organic portion was extracted with H2O (3 x 15 mL) and solvent was removed under
reduced pressure. The resulting oil was purified by column chromatography
(hexanes:EtOAc, 5:1). The starting material 68 was recovered (1.4 g) and compound 69
was precipitated from the column fractions using hexanes to give 0.12 g (5%): mp 60-61
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°C (lit182 50-60 °C, lit183 67-68 °C); 1H NMR (DMSO-d6) δ 7.95-8.05 (m, 2H, ArH), 8.31
(s, 1H, ArH), 10.19 (s, 1H, OH).
4-Chloro-2-nitro-1-(2-nitrovinyl)benzene (70). Compound 70 was attempted to be

synthesized by a literature procedure for a similar compound.174 Ammonium acetate
(0.02 g, 0.30 mmol) was added to a solution of 69 (0.10 g, 0.54 mmol) in CH3NO2 (1.0
mL). The reaction mixture was heated at reflux for 5.5 h then allowed to cool to room
temperature. The solution was concentrated under reduced pressure and the crude product
was triturated in cold CH3OH (1 mL) and the solid removed by filtration. The filtrate was
concentrated under reduced pressure. Neither column chromatography (hexanes:EtOAc,
4:1) nor Kugelrohr distillation could purify the product.
(4-Chloro-2-nitrophenyl)(1H-imidazol-1-yl)methanone (72). Compound 72 was

synthesized according to a literature procedure.175 Carbonyldiimidazole (1.2 g, 7.5 mmol)
was added to a suspension of 71 (1.5 g, 7.5 mmol) in THF (10 mL); CH3NO2 (2.0 mL)
and K2CO3 (1.1 g, 8.2 mmol) were added in THF (8 mL). The reaction mixture was
allowed to stir and heated at reflux for 4 h then allowed to cool to room temperature and
the solvent removed under reduced pressure. The oily residue was dissolved in EtOAc
(25 mL) and extracted with H2O (3 x 25 mL), washed with brine (10 mL), and dried
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified
by column chromatography (EtOAc:CH3OH, 9:1) to give a solid compound 72: mp 139140 °C; 1H NMR (DMSO-d6) δ 7.18 (s, 1H), 7.73 (s, 1H), 8.04-8.23 (m, 3H), 8.505 (s,
1H).
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4-Chloro-2-nitrobenzylbromide (75). This compound was prepared according to a

literature procedure.184 Benzoyl peroxide (0.54 g, 2.2 mmol) was slowly added to a
stirred solution of 4-chloro-2-nitrotoluene (68) (22.3 g, 130.0 mmol) and Nbromosuccinamide (23.1 g, 130.0 mmol) in CCl4 (200 mL). The reaction mixture was
heated at reflux for 4 h, then irradiated with a 250 W light bulb for an additional 65 h.
After cooling to room temperature the suspension was filtered and the filtrate was washed
with H2O (2 x 50 mL). The organic portion was dried (MgSO4) and the solvent was
removed under reduced pressure to give a brown oil. Crystals formed upon the edition of
Et2O and petroleum ether. The remaining oil was purified by column chromatography
(hexanes:EtOAc, 30:1) to give yellow crystals 14.5 g (45%): mp 38-39 °C (lit184 4041°C, hexanes).
2,3-Bis(4-chloro-2-nitrophenyl)propanenitrile (77). Method A. Compound 77 was

prepared according to a literature procedure for a similar compound.177 Sodium cyanide
(0.37 g, 7.5 mmol) was dissolved in anhydrous DMSO (2.4 mL) under N2 atmosphere at
10-15 °C. Concentrated H2SO4 (0.25 g, 2.5 mmol) was added by pipette and the mixture
was allowed to stir for 10 min. A solution of 75 (0.63 g, 2.5 mmol) in anhydrous DMSO
(1.1 mL) was added at -5 °C. The frozen suspension was allowed to warm to 5 °C. A blue
precipitate formed then the solution turned brown. The solution was allowed to stir at 5
°C for 3 h. The reaction mixture was poured into ice water (25 mL). The suspension was
extracted with EtOAc (3 x 15 mL). The organic portion was washed with brine (15 mL),
dried (Na2SO4) and the solvent removed under reduced pressure. A crude brown oily
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solid (0.50 g) was recrystallized from a mixture of Et2O and CH3OH to give 0.1 g of a
beige solid: mp 155-157 °C; 1H NMR (CDCl3) δ 3.45-3.51 (d, 1H), 3.78-3.82 (d, 1H),
5.12-5.16 (t, 1H), 7.29 (s, 2H), 7.42 (d, 1H), 7.63-7.73 (m, 3H), 8.08 (s, 2H).
Method B. Sodium cyanide (23.48 g, 490 mmol) was dissolved in H2O (133 mL).

Compound 75 (12 g, 49.01 mmol) was added as a solution in CH2Cl2 (30 mL) with
tetrabutylammonium bromide (0.05 g). The biphasic solution was allowed to vigorously
stir for 30 min then separated. The organic portion was washed with H2O (3 x 100 mL),
dried (Na2SO4), and the solvent evaporated. The crude product was separated by flash
chromatography (hexanes:EtOAc, 10:1; hexanes:EtOAc, 4:1, hexanes:EtOAc, 1:1). The
collected fractions solvent was removed under reduced pressure and the product was
recrystallized from a mixture of hexanes and Et2O to give a pale, yellow solid: mp 149150 °C.
Method C. Sodium cyanide (1.0 g) was dissolved in H2O (5 mL). Hydrobromic acid was

added in a dropwise manner until approximately pH 1-2. Compound 75 (0.1 g) was added
as a solution in CH2Cl2 (10 mL). Addition of tetrabutylammonium bromide did not
initiate the reaction.
Method D. Potassium cyanide (0.2 g) was suspended in acetonitrile (2 mL) and 18-

crown-6 (~0.05 g) was added. Compound 75 (0.05 g) was added and the solution
immediately turned blue then dark brown. After 1 h the starting material was consumed
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and TLC comparison of the product was consistent with products from both Methods A
and B.
B. Log P Analysis

High-performance liquid-chromatography was performed on a Varian ProStar
(Model 210, Varian Inc. Palo Alto, CA). Compounds were dissolved in aqueous
acetonitrile (~0.7 mg/mL; ~85%). Each solution was filtered a total of four times; twice
through two separate 0.45 μm Teflon filters. An ammonium acetate buffer was made
using HPLC-grade water (Spectrum, Gardena, CA) and ammonium hydroxide (28% NH3
in H2O; Sigma-Aldrich) and acetic acid (99.5%; Sigma-Aldrich), the pH was measured
using a pH meter and the pH was adjusted to 6.93-7.40. A Microsorb-MV 100 CN
column (particle size 5 μm, 4.6 mm i.d. x 250 mm l.; Varian Inc,. Palo Alto, CA), was
equilibrated with HPLC-grade aceonitrile and the ammonium acetate buffer solution until
a standard baseline and constant pressure were achieved. The column was set to run in
isocratic mode for 30 min and detect at a wavelength of 254 nm.
1. Standards

A sample (30 μL) of one of the standards (i.e., acetanilide, benzophenone,
naphthalene, diphenylamine, imidazole) or uracil was injected into a 20 µL loop and the
retention time from the elution peak was recorded. At the end of 30 min cycle another 30
μL sample was run. This was repeated a third time then the column was washed by
running it without a sample in graduated mode 80% to 20% acetonitrile. This process of
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running three samples at one concentration of acetonitrile then washing the column was
repeated for each sample at each concentration of acetonitrile used (40%, 50%, 60%, and
70%).
The average retention time for each standard and uracil was calculated for each
concentration of acetonitrile (40%, 50%, 60%, and 70%). The relative retention time
(RRT) to uracil was calculated for each compound at each concentration of acetonitrile
by subtracting the average retention time of uracil from the average retention time of the
standard (See Appendix A).
The log of the capacity factor ( logk ' ) was calculated for each compound at each
concentration of acetonitrile by taking the log of RRT divided by the average retention
time of uracil (See Appendix A).
The logk ' values were plotted on the y-axis and the concentration of acetonitrile
was plotted on the x-axis separately for each standard. Linear regression analyses were
performed using GraphPad Prism (GraphPad Software Inc. La Jolla, CA) to give a linear
equation for each compound. The log kw' value is the y-intercept or the value when the
concentration of acetonitrile is 0%.
The log kw' values for each standard were plotted on the x-axis and their
experimental log P values from a shake-flask experiment were plotted on the y-axis.
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Linear regression analysis of this plot gave a standard curve equation (e.g., log P = 1.660
( log kw' ) + 1.285).
2. Halogen Series

The average retention time for each compound in the halogen series (i.e., 27, 2,
42-44, 35, 17) was calculated for each concentration of acetonitrile (55%, 65%, and

75%). The relative retention time (RRT) to uracil was calculated for each compound at
each concentration of acetonitrile by subtracting the average retention time of uracil from
the average retention time of each compound tested. The log capacity factor ( logk ' ) was
calculated for each compound at each concentration of acetonitrile by taking the log of
the RRT divided by the average retention time of uracil (See Appendix A).
The logk ' values were plotted on the y-axis and the concentration of acetonitrile
was plotted on the x-axis separately for each compound. Linear regression analyses were
performed using GraphPad Prism to give a linear equation for each compound. The
log kw' value is the y-intercept or the value when the concentration of acetonitrile is 0%.
By substituting their log kw' values into the standard curve equation the log P values were
obtained.
3. Quinazoline Series

The average retention time for each compound in the quinazoline series (i.e., 4648) was calculated for each concentration of acetonitrile (55%, 60%, 65%, 70% and
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75%). The relative retention time (RRT) to uracil was calculated for each compound at
each concentration of acetonitrile by subtracting the average retention time of uracil from
the average retention time of each compound tested. The log capacity factor ( logk ' ) was
calculated for each compound at each concentration of acetonitrile by taking the log of
the RRT divided by the average retention time of uracil (See Appendix A).
The logk ' values were plotted on the y-axis and the concentration of acetonitrile
was plotted on the x-axis separately for each compound. Linear regression analyses were
performed using GraphPad Prism to give a linear equation for each compound. The
log kw' value is the y-intercept or the value when the concentration of acetonitrile is 0%.
By substituting their log kw' values into the standard curve equation the log P values were
obtained.
C. Behavioral Studies
1. Animals

Male ICR mice (19-30 g) were used throughout the study (Harlan Laboratories,
Indianapolis, IN). Mice were housed in groups of 5-6 in solid-bottom plastic cages in a
temperature (~22 °C)- and humidity (~50%)-controlled room. A standard 12:12 h
dark:light cycle (lights on at 0700 h) was used, and food and water were available ad lib.
The experiments were conducted according to standards set by the Institutional Animal
Care and Use Committee (IACUC) of Virginia Commonwealth University and the NIH
Guide for Care and Use of Laboratory Animals. Mice were allowed to adapt to the testing
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environment at least 1 h prior to any treatment, and weighed 30 min prior to the start of
the experiments.
2. Drugs

Ondansetron hydrochloride (Zofran®, Lot CO99723; GlaxoSmithKline) was
purchased from MCVH-Pharmacy. Fluoxetine hydrochloride (Prozac®, Batch 4A/80352;
Eli Lilly) was purchased from Tocris. Desipramine hydrochloride (Norpramin®, Lot
86H0942; Aventis Pharm) and imipramine hydrochloride (Tofranil®, Lot 27H1380;
Novartis) were purchased from Sigma. Compound 2 was used as a nitrate salt,
compounds 46 and 47 were used as HCl salts, and compound 48 was used as an HBr salt;
these four compounds were synthesized in our laboratory. Solutions were prepared fresh
daily; all drugs were dissolved in 0.9% saline and administered to mice in a total volume
of 10 mL/kg body weight by intraperitoneal (ip) injections. One exception was that
solutions of compound 48 were not made fresh daily but were refrigerated overnight and
used over a two-day period since very little of this compound was in stock and the
synthesis is more extensive than the other quinazoline analogs.133
3. Tail Suspension Test

The mice were allowed to adapt to the room and to a white noise generator (to
block out ambient noises from the surrounding hallways) for at least 2 h prior to the test;
tests were conducted between 1000 and 1500 h. Mice, naïve to the test apparatus, were
suspended ~1.5 cm from the tip of their tail with industrial grade Duct Tape to a bar 60
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cm above a flat bench. The experimentor/rater was unaware of the experimental
conditions (drug, drug dose) for individual animals. A random number table was used to
determine the order the drugs were administered to the mice.185 The mice were treated
with either saline (30 min pre-injection time), imipramine (20 mg/kg; 30 min preinjection time), desipramine (20 mg/kg; 30 min pre-injection time), fluoxetine (20 mg/kg,
30 min pre-injection time), ondansetron (0.1 µg/kg, 30 min pre-injection time), MD-354
(0.1, 1.0, 3.0, 10, or 30 mg/kg; 30 min pre-injection time), 46 (0.1, 0.3, 1.0, 3.0, 10, or 30
mg/kg; 30 min pre-injection time), 47 (0.1, 0.3, 1.0, 3.0, 10, or 30 mg/kg; 30 min preinjection time), or 48 (0.1, 0.3, 1.0, 3.0, or 10 mg/kg; 30 min pre-injection time). Drug
doses and pre-injection times for the standard agents were identical with what has been
previously reported.15,155 The mice were only tested once and each dose of test agent was
studied in 8-11 mice (n = 8-11 mice/treatment). The six minute suspension test was
captured by video recording either with a Logitech Quickcam Pro for Notebooks or
Nikon Coolpix S210 and Pinnacle USB-video capture device. The immobility time for
each mouse was determined by viewing each mouse’s 6 min trial and recording the
immobility time; each trial was reviewed and scored in triplicate and the mean of the
three scores was used. A mouse was considered immobile when it was making no active
escape movements but included passive swaying. A mouse was considered mobile when
it was making running motions, body jerks, or attempting to catch its tail.

117
4. Locomotor Activity Assay

The mice were allowed to adapt to the room for at least 1 h prior to the test; tests
were conducted between 0800 and 1630 h. Mice, naïve to the test apparatus, were placed
in individual TruScan Activity System (Coulbourn Instruments, Allentown, PA)
photocell arena chambers (model E63-10; 26 cm x 26 cm x 39 cm). The walls of the
chamber were transparent and surrounded by two rings of infrared photodetectors (model
E63-12). Each ring contained an array of 16 x 16 infrared detectors (spaced 1.524 cm (0.6
in) apart). These rings were interfaced to a computer for the monitoring of the
coordinates of each mouse’s location. A random number table was used to determine the
order the drugs were administered.185 The mice were treated with saline (0 min preinjection time), 46 (0.3 mg/kg; 0 min pre-injection time), or 47 (1.0 or 3.0 mg/kg; 0 min
pre-injection time). The mice were only tested once and each dose of test agent was
studied in 12-13 mice (n = 12-13 mice/treatment). The behavioral analysis examined 14
measures of activity: movement episodes, movement time (s), movement distance (cm),
jumps, retraced local movements, retraced local movement episodes, retraced local
movement time (s), margin distance traveled (cm), margin time (s), center arena entries,
center distance (cm), center time (s), velocity (cm/s), and vertical plane entries.

5. Statistical Analysis

Data for immobility times and for each measure of locomotor activity were
analyzed statistically by a one-way analysis of variance (ANOVA) followed by either the
Dunnett’s t-test or the Newman-Keuls post-hoc comparison test using GraphPad Prism
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(GraphPad Software Inc. La Jolla, CA). A Grubb’s test for outliers was used to identify
outliers with an α = 0.05.

D. Molecular Modeling

The homology model studies were performed on a Silicon Graphics workstation
using Sybyl (Version 7.3.3; Tripos Inc. St. Louis, MO), Modeller (Version 9.3;
University of California San Francisco, San Francisco, CA), Chimera (Version 1, Build
2422; University of California San Francisco, San Francisco, CA), GOLD (Version 3.1;
Cambridge Crystallographic Data Centre, Cambridge, UK), and AutoDock (Version 4;
Scripps Research Institute, La Jolla, CA). All ligands were built in Sybyl and given AM1
charges and geometries based on MOPAC. The alignment of several LGICs and AChBPs
was performed in Clustal X186 using the following accession numbers: 47519841 (5HT3A; Homo sapiens), 7305175 (5-HT3A; Mus musculus), 38327554 (GABAA α1;
Homo sapiens), 4503863 (GABAA β1; Homo sapiens), 34734071 (GABAA δ; Homo
sapiens), 12314059 (GABAA ρ2; Homo sapiens), 119372310 (Gly α1; Homo sapiens),
and 1346173 (Gly β; Homo sapiens). PDBs used for alignment are 1i9b (AChBP;
Lymnaea stagnalis), 2bg9 (nAChR; Torpedo marmorata), 2bj0 (AChBP; Bulinus
truncates), 2byn (AChBP; Aplysia californica), and 2qc1 (nAChR α1 and αbungarotoxin; Bungarus multicinctus).
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Appendix A

HPLC Data for Standards in Log P Analysis
Compound
Uracil
Acetanilide

RT
RT
RRT

logk '
Benzophenone

RT
RRT

logk '
Naphthalene

RT
RRT

logk '
Diphenylamine

RT
RRT

logk '
Imidazole

RT
RRT

logk '

Acetonitrile
50%
60%
4.032
4.136
4.745
4.664
0.713
0.528
-0.753 -0.894

70%
4.034
4.541
0.507
-0.900

8.551
4.578
0.062

5.478
1.446
-0.445

4.928
0.792
-0.718

4.593
0.559
-0.858

9.119
5.146
0.112

6.256
2.224
-0.258

5.054
0.918
-0.654

5.016
0.982
-0.613

10.467
6.494
0.213

6.502
2.470
-0.213

4.750
0.614
-0.828

4.954
0.920
-0.642

4.859
0.886
-0.652

4.924
0.892
-0.655

5.577
1.441
-0.458

5.226
1.192
-0.529

40%
3.973
5.360
1.387
-0.457

HPLC Data for Halogen Series in Log P Analysis
Compound
Uracil
27

RT
RT
RRT

logk '
2

RT
RRT

logk '

55%
3.314
10.093
6.779
0.311
9.286
5.972
0.256

Acetonitrile
65%
3.391
9.833
6.441
0.279
9.423
6.032
0.250

75%
3.466
10.596
7.130
0.313
10.168
6.703
0.286
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42

RT
RRT

logk '
43

RT
RRT

logk '
44

RT
RRT

logk '
35

RT
RRT

logk '
Uracil
17

RT
RT
RRT

logk '

9.498
6.184
0.271

9.529
6.138
0.258

10.083
6.618
0.281

11.039
7.725
0.368

10.468
7.077
0.319

10.801
7.336
0.326

11.792
8.478
0.408

10.989
7.598
0.350

10.980
7.514
0.336

13.646
10.332
0.494

11.518
8.127
0.380

10.630
7.164
0.315

3.045
8.439
5.394
0.248

3.239
8.417
5.178
0.204

3.380
9.299
5.919
0.243

HPLC Data for Quinazoline Series in Log P Analysis

Compound
Uracil
46

RT
RT
RRT

logk '
47

RT
RRT

logk '
48

RT
RRT

logk '

55%
3.314
11.297
7.983
0.382

Acetonitrile
60%
65%
3.209
3.391
10.893 11.059
7.684
7.667
0.379
0.354

70%
3.435
11.207
7.772
0.355

75%
3.466
11.276
7.810
0.353

11.253
7.939
0.379

10.801
7.593
0.374

11.424
8.033
0.374

11.471
8.036
0.369

11.481
8.016
0.364

11.431
8.117
0.389

10.867
7.658
0.378

11.463
8.071
0.377

11.441
8.007
0.368

11.588
8.122
0.370
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